[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1308
6. Chiu CY, Wu YC, Jenq SF, Jap TS: Mutations in low-density lipoprotein receptor gene as a cause of hypercholesterolemia in Taiwan. Metabolism; 2005 Aug;54(8):1082-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified 6 mutations in LDLR gene, including heterozygous missense mutations I420T (ATC-->ACC), C660W (TGC-->TGG), H562Y (CAC-->TAC), and A606T (GCC-->ACC), and a heterozygous and a homozygous mutation in codon P664L (CCG-->CTG) as well as a homozygous large deletion of exons 6 to 8.

  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092059.001).
  • [ISSN] 0026-0495
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, LDL
  •  go-up   go-down


7. Abou Chakra CN, Pariente A, Pinet M, Nkeng L, Moore N, Moride Y: Case series in drug safety: a review to determine characteristics and quality. Drug Saf; 2010 Dec 01;33(12):1081-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adverse effects involved mainly the skin (18.5%) and the circulatory system (13.8%).
  • The main suspected drug classes (Anatomical Therapeutic Chemical classification) were nervous system drugs (23.1%) and antineoplastic and immunomodulating agents (20.0%).

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2007 Sep;80(3):231-7 [17956013.001]
  • [Cites] Therapie. 2009 Jul-Aug;64(4):289-94 [19804709.001]
  • [Cites] Eye (Lond). 2007 Apr;21(4):547-9 [16456589.001]
  • [Cites] CMAJ. 2005 Mar 15;172(6):765-7 [15767610.001]
  • [Cites] J Rheumatol. 2008 Mar;35(3):537-8 [18203307.001]
  • [Cites] Drug Saf. 2006;29(8):687-96 [16872242.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):808-12 [16700082.001]
  • [Cites] Intern Med J. 2006 Mar;36(3):162-9 [16503951.001]
  • [Cites] J Ocul Pharmacol Ther. 2004 Apr;20(2):179-82 [15117574.001]
  • [Cites] J Mich Dent Assoc. 2005 Nov;87(11):44-9 [16372548.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 May;16(5):581-7 [17471601.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):807-11 [12755552.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Apr;57(1):89-91 [11372600.001]
  • [Cites] Drug Saf. 2007;30(5):367-73 [17472416.001]
  • [Cites] Cutan Ocul Toxicol. 2008;27(1):5-9 [18330828.001]
  • [Cites] Drug Saf. 2008;31(12):1115-23 [19026028.001]
  • [Cites] Therapie. 1997 Mar-Apr;52(2):123-7 [9231506.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2006 Jul-Aug;72(4):286-9 [16880575.001]
  • [Cites] J Am Acad Dermatol. 2007 Apr;56(4):624-8 [17240478.001]
  • [Cites] Ophthalmology. 2008 Dec;115(12):2282-5 [18930555.001]
  • [Cites] Pediatrics. 2005 Nov;116(5):e675-80 [16230465.001]
  • [Cites] Drug Saf. 2006;29(2):143-9 [16454541.001]
  • [Cites] Br J Clin Pharmacol. 2008 Nov;66(5):689-94 [18754840.001]
  • [Cites] Reumatismo. 2005 Jan-Mar;57(1):44-51 [15776146.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):e19-22 [16779736.001]
  • [Cites] Drugs Aging. 2004;21(7):479-84 [15132714.001]
  • [Cites] Rev Med Chil. 2006 Jul;134(7):875-82 [17130971.001]
  • [Cites] Ophthalmology. 2006 Feb;113(2):308-14 [16406545.001]
  • [Cites] Ann Dermatol Venereol. 2003 Nov;130(11):1051-5 [14724542.001]
  • (PMID = 21077699.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  •  go-up   go-down


8. Sipos JA, Mazzaferri EL: The therapeutic management of differentiated thyroid cancer. Expert Opin Pharmacother; 2008 Oct;9(15):2627-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic management of differentiated thyroid cancer.
  • BACKGROUND: The management of thyroid cancer is difficult because the tumors comprise a wide range of biologic behaviors, from small papillary thyroid microcarcinomas that pose little or no threat to survival for the patient, to anaplastic thyroid cancers that are arguably the most lethal tumor.
  • Although it may be difficult initially to determine at which end of the prognostic spectrum a patient resides, one can ordinarily estimate a patient's risk for tumor recurrence and mortality based on a triad of features as simple as the patient's age at the time of diagnosis, the tumor stage at presentation, and its initial response to therapy.
  • This is largely because randomized controlled trials are lacking as a result of the low incidence and generally favorable prognosis of the disease.
  • The treatment of these tumors rests on a fine balance of providing care that reflects the anticipated course of the disease without overtreating the patient or providing reassurance that is unfounded.
  • OBJECTIVE: To outline the treatment strategy for patients with differentiated thyroid cancer based on the available literature and to guide clinicians through a management algorithm utilizing patient and tumor characteristics.
  • METHODS: This review is limited to the treatment of patients with differentiated thyroid cancer - papillary and follicular thyroid cancer - and the standard therapy required for the majority of patients.
  • RESULTS/CONCLUSION: The treatment of differentiated thyroid cancer requires a multidisciplinary approach, involving an experienced surgeon, radiologists and an endocrinologist.
  • There are many unanswered questions in the management algorithm and ongoing research is needed to further define the best treatment strategy for patients with differentiated thyroid cancer.
  • [MeSH-major] Thyroid Neoplasms / therapy
  • [MeSH-minor] Cell Differentiation. Combined Modality Therapy. Hormone Replacement Therapy. Humans. Lymph Node Excision. Postoperative Complications. Radiotherapy Dosage. Thyroid Hormones / administration & dosage. Thyroidectomy. Thyrotropin / antagonists & inhibitors

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803450.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Thyroid Hormones; 9002-71-5 / Thyrotropin
  • [Number-of-references] 102
  •  go-up   go-down


9. Pelosi G, Fumagalli C, Trubia M, Sonzogni A, Rekhtman N, Maisonneuve P, Galetta D, Spaggiari L, Veronesi G, Scarpa A, Malpeli G, Viale G: Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Res; 2010 Oct;30(10):4269-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Twenty typical carcinoids (TC), 11 atypical carcinoids (ATC), 11 large cell neuroendocrine carcinomas (LCNEC) and 16 small cell lung carcinomas (SCLC) were analyzed for RASSF1 promoter methylation, mRNA and protein expression, and loss of 3p21.3 locus.
  • A correlation was found between 3p21.3 allelic loss and decrease of RASSF1 A/E mRNA (p=0.023) and protein (p=0.043) expression in ATC, suggesting that 3p21.3 allelic loss contributed to the loss of gene expression.
  • [MeSH-minor] Adenocarcinoma / genetics. Aged. Carcinoma, Small Cell / genetics. Carcinoma, Squamous Cell / genetics. DNA Methylation. Female. Genes, Tumor Suppressor. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Male. Middle Aged. Oncogenes. Promoter Regions, Genetic. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036752.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


10. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR: Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab; 2009 Jun;94(6):2199-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
  • CONTEXT: Focal adhesion kinase (FAK) and Src are overexpressed and activated in many cancers and have been associated with tumor progression.
  • The role of the Src-FAK complex has not been characterized in papillary and anaplastic thyroid cancer (PTC and ATC).
  • OBJECTIVE: The goal of this study was to determine the role of Src and FAK in the growth and invasion of PTC and ATC.
  • DESIGN: PTC and ATC cells were treated with the oral Src inhibitor, AZD0530, to determine the consequences of Src inhibition using growth and invasion assays.
  • RESULTS: AZD0530 treatment inhibited the growth and invasion in four of five thyroid cancer cell lines, and inhibition did not correlate with basal levels of phospho-Src.
  • Instead, we show for the first time that FAK, a critical substrate and effector of Src, is phosphorylated at tyrosine residue 861 (pY861) in PTC and ATC cells, and high levels of phospho-FAK correlate with AZD0530 sensitivity.
  • CONCLUSIONS: Inhibition of the Src-FAK complex represents a promising therapeutic strategy for patients with advanced thyroid cancer, and phospho-FAK represents a potential biomarker for response.

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Nov 20;19(49):5636-42 [11114744.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):710-5 [15483349.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10566-70 [10187851.001]
  • [Cites] Surgery. 2004 Dec;136(6):1212-7 [15657578.001]
  • [Cites] Surgery. 2005 Aug;138(2):269-74 [16153436.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):4-6 [16413465.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1623-9 [16533790.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1785-93 [16551863.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1136-44 [16731745.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6521-9 [16818623.001]
  • [Cites] J Med Chem. 2006 Nov 2;49(22):6465-88 [17064066.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):16-20 [17179987.001]
  • [Cites] Biochem Pharmacol. 2007 Mar 1;73(5):597-609 [16997283.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2800-8 [17363602.001]
  • [Cites] Ann Oncol. 2007 Nov;18(11):1765-73 [17426060.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7232-6 [18094400.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2358-62 [18258742.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3323-33 [18451159.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201 [18381570.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • (PMID = 19293266.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100560; United States / NCI NIH HHS / CA / P30 CA 046934; United States / NCI NIH HHS / CA / P30 CA046934; United States / NCI NIH HHS / CA / R01 CA100560; United States / NCI NIH HHS / CA / K12 CA086913
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzodioxoles; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 9KD24QGH76 / saracatinib; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src)
  • [Other-IDs] NLM/ PMC2690419
  •  go-up   go-down


11. Elisei R, Vivaldi A, Agate L, Ciampi R, Molinaro E, Piampiani P, Romei C, Faviana P, Basolo F, Miccoli P, Capodanno A, Collecchi P, Pacini F, Pinchera A: All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. J Clin Endocrinol Metab; 2005 Apr;90(4):2403-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.
  • Conventional chemotherapy and radiotherapy are ineffective for the treatment of advanced thyroid tumors like poorly differentiated papillary, anaplastic, and medullary thyroid cancer.
  • In the attempt to evaluate the possibility of using retinoic acid (RA) in the treatment of thyroid cancer refractory to conventional therapy, we studied the effect of all-trans-RA treatment on five human thyroid cancer cell lines.
  • We found that WRO and NPA, derived from follicular and poorly differentiated human thyroid carcinoma, respectively, showed a growth inhibition after 25 and 21 d of RA treatment.
  • On the contrary, we did not observe any recovery of mRNA expression of thyroid-specific genes and in particular of the sodium iodide symporter gene.
  • The main difference between the all-trans-RA responding cells (WRO and NPA) and the nonresponding cells [ARO, FRO (derived from human anaplastic thyroid tumors) and TT (derived from human medullary thyroid tumor)] was the basal and all-trans-RA induced RA receptor (RAR)beta mRNA expression.
  • Interestingly, 14 thyroid tumors (10 papillary and four anaplastic) showed a significant lower expression of RARbeta mRNA when compared with normal thyroid tissues.
  • In agreement with this result, only 30% of papillary thyroid carcinomas analyzed were positive for RARbeta protein expression with a degree of expression that was much lower than that found in normal thyroid tissue.
  • In conclusion we found that all-trans-RA treatment can determine a significant in vitro growth inhibition especially in differentiated thyroid tumor-derived cell lines but it seems unable to reinduce the expression of thyroid-specific genes and in particular to reinduce the ability to take up iodine.
  • The finding of a basal and RA-induced RARbeta mRNA expression only in cell lines responding to all-trans-RA suggests that the growth inhibition might be mediated by RARbeta.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. RNA, Messenger / analysis. Receptors, Retinoic Acid / genetics. Thyroid Gland / metabolism. Thyroid Neoplasms / drug therapy. Tretinoin / pharmacology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15623821.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor beta; 5688UTC01R / Tretinoin
  •  go-up   go-down


12. García-Rostán G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J, Santoro M: Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res; 2005 Nov 15;65(22):10199-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation of the PIK3CA gene in anaplastic thyroid cancer.
  • The phosphatidylinositol 3'-kinase (PI3K) pathway is frequently activated in thyroid carcinomas through the constitutive activation of stimulatory molecules (e.g., Ras) and/or the loss of expression and/or function of the inhibitory PTEN protein that results in Akt activation.
  • Recently, it has been reported that somatic mutations within the PI3K catalytic subunit, PIK3CA, are common (25-40%) among colorectal, gastric, breast, ovarian cancers, and high-grade brain tumors.
  • In this study, 13 thyroid cancer cell lines, 80 well-differentiated thyroid carcinomas of follicular (WDFC) and papillary (WDPC) type, and 70 anaplastic thyroid carcinomas (ATC) were investigated, by PCR-direct sequencing, for activating PIK3CA mutations at exons 9 and 20.
  • Nonsynonymous somatic mutations were found in 16 ATC (23%), two WDFC (8%), and one WDPC (2%).
  • In 18 of the 20 ATC cases showing coexisting differentiated carcinoma, mutations, when present, were restricted to the ATC component and located primarily within the kinase domain.
  • In addition, activation of Akt was observed in most of the ATC harboring PIK3CA mutations.
  • These findings indicate that mutant PIK3CA is likely to function as an oncogene among ATC and less frequently well-differentiated thyroid carcinomas.
  • The data also argue for a role of PIK3CA targeting in the treatment of ATC patients.
  • [MeSH-major] Carcinoma / genetics. Mutation, Missense. Phosphatidylinositol 3-Kinases / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma, Follicular / enzymology. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / pathology. Amino Acid Substitution. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Growth Processes / genetics. Cell Line, Tumor. Enzyme Activation. Genes, p53 / genetics. Genes, ras / genetics. Humans. Oncogene Protein v-akt / metabolism. Proto-Oncogene Proteins B-raf / genetics


13. Murugan AK, Bojdani E, Xing M: Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun; 2010 Mar 12;393(3):555-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
  • In the present study, we investigated IDH1 and IDH2 mutations in follicular thyroid cancer (FTC) and anaplastic thyroid cancer (ATC), with the latter, like glioblastoma, having a rapidly aggressive and lethal clinical course.
  • By direct genomic DNA sequencing, we analyzed exon 4 of the IDH1 and IDH2 genes that harbored the mutation hot spots codon 132 and 172 of the two genes in glioblastoma, respectively, in 12 thyroid cancer cell lines, 20 FTC, and 18 ATC tumor samples.
  • A novel homozygous G367A IDH1 mutation, resulting in a G123R amino acid change in codon 123, was identified in a case of ATC.
  • A previously described IDH1 V71I mutation was found in a case of FTC and a case of ATC and no mutations were found in the cell lines.
  • The overall prevalence of mutations was thus 1/20 (5%) in FTC and 2/18 (11%) in ATC.
  • We did not find mutation in the IDH2 gene in these thyroid cancer cell lines and tumor samples.
  • Thus, functionally relevant IDH1 mutations can also occur in thyroid cancer, particularly ATC, suggesting a potential tumorigenic role of the IDH1 system that could represent a new therapeutic target for thyroid cancer.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):101-11 [18097548.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):525-38, xi [18502341.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):353-5 [19378339.001]
  • [Cites] Cell Cycle. 2009 Jul 1;8(13):2122-4 [19411838.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] Arch Microbiol. 1997 Nov;168(5):412-20 [9325430.001]
  • (PMID = 20171178.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA134225-01A2; United States / NCI NIH HHS / CA / R01 CA113507; United States / NCI NIH HHS / CA / CA134225-01A2; United States / NCI NIH HHS / CA / R01CA134225-01; United States / NCI NIH HHS / CA / R01 CA134225
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  • [Other-IDs] NLM/ NIHMS182112; NLM/ PMC2838977
  •  go-up   go-down


1
Advertisement
4. Subramanian M, Pilli T, Bhattacharya P, Pacini F, Nikiforov YE, Kanteti PV, Prabhakar BS: Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab; 2009 Apr;94(4):1467-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.
  • AIM: The aim of the study was to investigate the expression and function of the IG20 gene in thyroid cancer cell survival, proliferation, and apoptosis.
  • METHODS: We determined the expression levels of the major isoforms of IG20 by quantitative RT-PCR in normal and thyroid tumor tissues/cell lines.
  • We evaluated the functional consequence of IG20 knockdown in WRO (follicular carcinoma) and FRO (anaplastic carcinoma) thyroid cancer cell lines by measuring spontaneous, TNFalpha-related apoptosis-inducing ligand (TRAIL), and TNFalpha-induced apoptosis.
  • RESULTS: The IG20 gene expression levels were higher in benign and malignant thyroid tumors and in WRO and FRO cells relative to normal tissues.
  • CONCLUSION: IG20 knockdown renders WRO cells more susceptible to spontaneous, TRAIL-, and TNFalpha-induced apoptosis and thus demonstrates the prosurvival function of the IG20 gene in thyroid cancer.
  • These observations, combined with overexpression of IG20 noted in thyroid tumor tissues, may suggest a potential role in thyroid cancer survival and growth and indicate that IG20 may be targeted either alone or in conjunction with TRAIL or TNFalpha treatment in certain thyroid cancers.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4122-9 [10945619.001]
  • [Cites] Nat Med. 1999 Feb;5(2):157-63 [9930862.001]
  • [Cites] J Virol. 2003 Nov;77(22):11964-72 [14581533.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8768-76 [14695193.001]
  • [Cites] Int J Cancer. 2004 Mar10;109(1):24-37 [14735464.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1076-87 [14716293.001]
  • [Cites] Oncogene. 2004 Aug 12;23(36):6083-94 [15208670.001]
  • [Cites] Nature. 1993 Aug 26;364(6440):806-9 [7689176.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2607-12 [8675585.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):255-60 [10209153.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Oncogene. 2006 Oct 12;25(47):6252-61 [16682944.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):11715-21 [17314102.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 [18088233.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):347-51 [18223207.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7352-61 [18794122.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12069-75 [9115275.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47202-11 [11577081.001]
  • (PMID = 19190106.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107506; United States / NCI NIH HHS / CA / 5R01CA107506
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Death Domain Receptor Signaling Adaptor Proteins; 0 / Guanine Nucleotide Exchange Factors; 0 / MADD protein, human; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2682475
  •  go-up   go-down


15. Wemeau JL, Do Cao C: [Anaplastic thyroid carcinoma]. Ann Endocrinol (Paris); 2008 Jun;69(3):174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic thyroid carcinoma].
  • [Transliterated title] Cancers anaplasiques de la thyroïde.
  • Anaplastic thyroid carcinoma may represent the ultimate dedifferentiation step of thyroid tumorigenesis and is one of the poorest cancers in human.
  • It accounts for less than 2% of thyroid cancers and affects older patients in their sixth to eighth decade.
  • Usual clinical presentation is a rapidly growing thyroid mass invading surrounding structures with compressive symptoms.
  • Though cytological results obtained by fine needle aspiration may be suggestive of diagnosis, tissue biopsy for immunohistochemical study can be necessary to exclude lymphoma and to validate aggressive therapies.
  • Patients developing anaplastic thyroid cancer must be referred urgently in cancer centers to plan multimodality therapeutic approach depending on their performance status.
  • Such treatment can provide control of locoregional disease but does not impact on overall survival in patients with distant metastases.
  • The prognosis is dismal with a mean survival of four to nine months after diagnosis.
  • Long survivors are patients with emerging disease presenting a resectable tumor and receiving adjuvant radiotherapy and/or chemotherapy.
  • Therapeutic researches investigate redifferenciation strategies and targeted therapies to inhibit EGF receptors and neoplastic angiogenesis.
  • Primary prevention of this lethal disease may consist of adequate treatment of differentiated thyroid cancers and goiters in elderly.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Goiter / complications. Goiter / therapy. Humans. Middle Aged. Thyroid Diseases / complications. Thyroid Diseases / therapy. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423422.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Cox S, Southby J: Apricitabine--a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs. Expert Opin Investig Drugs; 2009 Feb;18(2):199-209
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Apricitabine (ATC) is a nucleoside reverse transcriptase inhibitor (NRTI) being developed for the treatment of HIV.
  • ATC has promising antiviral activity, including against HIV-1 containing reverse transcriptase mutations that confer resistance to other NRTIs.
  • OBJECTIVES: This paper describes the development of ATC, including its in vitro activity, pharmacokinetics and clinical efficacy and safety.
  • METHODS: The current literature on ATC was reviewed.
  • RESULTS/CONCLUSIONS: ATC is a novel deoxycytidine NRTI with good antiviral activity, both in vitro and in treatment-naïve and treatment-experienced HIV-1-infected patients, including those with resistance to other NRTIs.
  • ATC may have a place in the treatment of patients who have failed previous treatment regimens due to the development of NRTI resistance as a replacement for existing drugs.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Deoxycytidine / analogs & derivatives. HIV Infections / drug therapy. Reverse Transcriptase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236266.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Reverse Transcriptase Inhibitors; 0W860991D6 / Deoxycytidine; K1YX059ML1 / apricitabine
  • [Number-of-references] 47
  •  go-up   go-down


17. Hemminki K, Eng C, Chen B: Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab; 2005 Oct;90(10):5747-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial risks for nonmedullary thyroid cancer.
  • CONTEXT: Reliable data on familial risks are important for clinical counseling and cancer genetics.
  • OBJECTIVE: We wanted to define familial risks for histopathology-specific nonmedullary thyroid cancers through parental and sibling probands.
  • SETTING: The study examines the nationwide Swedish Family-Cancer Database on 10.5 million individuals, containing families with parents and offspring.
  • PATIENTS: Cancer data were retrieved from the Swedish Cancer Registry from years 1958 to 2002, including 3292 patients with thyroid adenocarcinoma.
  • The Systematized Nomenclature of Medicine histology was available from 1993 onward, with 1449 papillary, 288 follicular, 148 anaplastic, and 68 Hurthle cell tumors.
  • RESULTS: The familial risk for papillary carcinoma was 3.21 and 6.24 when a parent and a sibling, respectively, were diagnosed with thyroid cancers.
  • The risks were highest for early onset cancers.
  • Thyroid adenocarcinoma was shown to be associated with melanoma and connective tissue tumors, and probably also with neurinomas (schwannomas).
  • Associations found in single comparisons with papillary thyroid cancer and other sites included right-sided colon, breast, ovarian, and kidney cancers.
  • CONCLUSIONS: The present findings were based on a limited number of cases, but they display a complex and heterogeneous pattern of familial nonmedullary thyroid cancer.
  • The high risk for papillary carcinoma among women requires clinical attention, although the absolute risks for this rare cancer are still low.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / genetics. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030170.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. O'Neill JP, Power D, Condron C, Bouchier-Hayes D, Walsh M: Anaplastic thyroid cancer, tumorigenesis and therapy. Ir J Med Sci; 2010 Mar;179(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid cancer, tumorigenesis and therapy.
  • BACKGROUND: Anaplastic thyroid cancer (ATC) is a fatal endocrine malignancy.
  • Recent insights into thyroid tumorigenesis, post-malignant dedifferentiation and mode of metastatic activity offer new therapeutic strategies.
  • METHODS: An extensive literature search of Medline and Pubmed was conducted to include all published reports on ATC.
  • CONCLUSIONS: Significant progress, in the last 5 years, has been made outlining thyroid tumorigenesis and the progression to anaplasia.
  • [MeSH-major] Thyroid Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cadherins. Cyclins. Disease Progression. Humans. Radiotherapy. Receptor, Epidermal Growth Factor. Vascular Endothelial Growth Factor A. beta Catenin

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):275-82 [16477625.001]
  • [Cites] Am J Surg. 2006 May;191(5):581-7 [16647341.001]
  • [Cites] Head Neck. 2003 Aug;25(8):662-70 [12884350.001]
  • [Cites] Head Neck. 2007 Aug;29(8):765-72 [17274052.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):686-94 [17001684.001]
  • [Cites] Growth Factors. 2006 Mar;24(1):13-9 [16393691.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1161-70 [17317825.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12 (2):600-7 [16428506.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1303-10 [17608770.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):987-96 [11238046.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):928-35 [15562011.001]
  • [Cites] Endocrine. 2007 Apr;31(2):105-13 [17873319.001]
  • [Cites] Ann Surg. 2000 Mar;231(3):329-38 [10714625.001]
  • [Cites] Surgery. 2006 Dec;140(6):899-905; discussion 905-6 [17188136.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10199-207 [16288007.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2515-22 [17695547.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3716-25 [15867367.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):370-9 [11788678.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Sep;131(9):585-90 [16021466.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):719-29 [17115102.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156(4):425-30 [17389456.001]
  • [Cites] Oncogene. 1989 Feb;4(2):159-64 [2648253.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):889-95 [15671766.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] World J Surg. 2007 May;31(5):969-77 [17483987.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1247-53 [11889195.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1330-5 [15739211.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):69-90 [12946479.001]
  • [Cites] BMC Cancer. 2005 Jul 19;5:80 [16029487.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):671-7 [10934169.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):621-8 [17270245.001]
  • [Cites] Cancer Lett. 1995 Aug 16;95(1-2):135-8 [7656221.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):302-8 [10634403.001]
  • [Cites] Eur J Cancer. 2002 Aug;38(12):1661-70 [12142058.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):179-84 [8423216.001]
  • [Cites] Thyroid. 1998 Aug;8(8):715-26 [9737368.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1030:69-77 [15659782.001]
  • [Cites] Nucl Med Biol. 2006 Oct;33(7):875-82 [17045167.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1569-79 [7478581.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64 [11833496.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 [14602780.001]
  • [Cites] Endocr Pathol. 2007 Spring;18(1):1-7 [17652794.001]
  • [Cites] J Surg Oncol. 2006 Dec 15;94(8):662-9 [17131411.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):632-40 [15827337.001]
  • [Cites] Head Neck. 1996 Jan-Feb;18(1):36-41 [8774920.001]
  • [Cites] Laryngoscope. 2007 Apr;117(4):674-9 [17429874.001]
  • [Cites] Mol Cancer Ther. 2007 Jun;6(6):1785-92 [17575107.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] Curr Biol. 2002 Jul 9;12(13):R458-60 [12121637.001]
  • [Cites] Arch Surg. 2007 Aug;142(8):717-27; discussion 727-9 [17709725.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):915-28 [12168049.001]
  • (PMID = 19662494.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cadherins; 0 / Cyclins; 0 / Vascular Endothelial Growth Factor A; 0 / beta Catenin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 54
  •  go-up   go-down


19. Maegele M: Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options. World J Emerg Med; 2010;1(1):12-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute traumatic coagulopathy: Incidence, risk stratification and therapeutic options.
  • A synopsis is presented of different retrospective analyses based upon datasets from severe multiply injured patients derived from the TR-DGU database (Trauma Registry of the Deutsche Gesellschaft fur Unfallchirurgie (DGU)/ German Society of Trauma Surgery) with respect to frequency, risk stratification and therapeutic options of acute traumatic coagulopathy (ATC).
  • METHODS: The synopsis of different analyses based upon the datasets from severe multiply injured patients derived from the TR-DGU database and development/validation of a scoring system (TASH-score = Trauma Associated Severe Hemorrhage) that allows an early and reliable estimation for the probability of massive transfusion as a surrogate for life-threatening hemorrhage after severe multiple injuries.
  • RESULTS: The high frequency of ATC upon emergency room admission is associated with significant morbidity and mortality in multiply injured patients.
  • The TASH-score is recognized as an easy-to-calculate and valid scoring system to predict the individual's probability for massive transfusion and thus ongoing life-threatening hemorrhage at a very early stage after severe multiple injuries.
  • CONCLUSION: An early aggressive management of ATC including a more balanced administration of blood products to improve outcome is advocated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25214935.001).
  • [ISSN] 1920-8642
  • [Journal-full-title] World journal of emergency medicine
  • [ISO-abbreviation] World J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4129771
  • [Keywords] NOTNLM ; Coagulopathy / Epidemiology / Management / Risk stratification / Trauma
  •  go-up   go-down


20. Sotome K, Onishi T, Hirano A, Nakamaru M, Furukawa A, Miyazaki H, Morozumi K, Tanaka Y, Iri H, Mimura Y: A rare case of anaplastic transformation within the metastatic site of the retroperitoneal region in a patient 17 years after total thyroidectomy for papillary carcinoma of the thyroid beginning with multiple bone metastases. Thyroid; 2007 Dec;17(12):1309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of anaplastic transformation within the metastatic site of the retroperitoneal region in a patient 17 years after total thyroidectomy for papillary carcinoma of the thyroid beginning with multiple bone metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Carcinoma, Papillary / pathology. Retroperitoneal Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177259.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H: Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis; 2009;9:61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The primary aims of this study were (i) to determine the quantity and pattern of antibiotic use in Austria between 1998 and 2007 and (ii) to analyze antibiotic esistance rates in relation to antibiotic consumption in important clinical situations in order to provide data for empirical therapeutic regimens for key indications.
  • METHODS: Consumption data and resistance data were obtained via the Austrian surveillance networks European Antimicrobial Resistance Surveillance System (EARSS) and European Surveillance on Antimicrobial Consumption (ESAC).
  • The Anatomical Therapeutic Chemical (ATC) classification and the Defined Daily Dose (DDD) measurement units were assigned to the data.
  • The percentage of nonsusceptible or intermediate penicillin-resistant pneumococcal isolates remained stable over this time period at around 5%.
  • [MeSH-major] Ambulatory Care / trends. Anti-Bacterial Agents / therapeutic use. Drug Resistance, Bacterial. Practice Patterns, Physicians' / trends. Prescriptions / statistics & numerical data

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Microbiol Infect. 2000 Feb;6(2):59-63 [11168073.001]
  • [Cites] Clin Microbiol Infect. 2008 Jan;14 Suppl 1:104-10 [18154533.001]
  • [Cites] Lancet. 2003 Dec 13;362(9400):1991-2001 [14683661.001]
  • [Cites] Lancet. 2005 Feb 12-18;365(9459):579-87 [15708101.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):401-7 [16735414.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):408-12 [16735415.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):413-7 [16735416.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):423-7 [16735418.001]
  • [Cites] Jpn J Infect Dis. 2006 Oct;59(5):299-05 [17060695.001]
  • [Cites] Urology. 2006 Dec;68(6):1169-74 [17169640.001]
  • [Cites] Clin Infect Dis. 2007 Apr 15;44(8):1091-5 [17366456.001]
  • [Cites] Am J Health Syst Pharm. 2007 Dec 1;64(23 Suppl 14):S3-21; quiz S22-4 [18029939.001]
  • [Cites] Med J Aust. 2008 Feb 18;188(4):209-13 [18279126.001]
  • [Cites] BMC Infect Dis. 2008;8:71 [18501015.001]
  • [Cites] J Infect. 2008 Sep;57(3):179-84 [18707763.001]
  • [Cites] Clin Infect Dis. 2008 Nov 1;47(9):1150-8 [18808361.001]
  • [Cites] Clin Infect Dis. 2001 Apr 15;32(8):1162-71 [11283805.001]
  • (PMID = 19439064.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2686702
  •  go-up   go-down


22. Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C, Newbold K: Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):518-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis.
  • PURPOSE: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive cancers, and the current protocol of hyperfractionated accelerated radiotherapy was initiated to improve survival while limiting toxicities.
  • METHODS AND MATERIALS: All patients with ATC from 1991 to 2002 were accrued and received megavoltage radiotherapy from the mastoid processes to the carina up to 60 Gy in twice-daily fractions of 1.8 and 2 Gy, 6 hours apart.
  • Local control data were available for 27 patients: 22% had a complete response, 26% had a partial response, 15% showed progressive disease, and 37% showed static disease.
  • There is a suggestion that younger patients with operable disease have longer survival, but this would require a larger study to confirm it.
  • [MeSH-major] Carcinoma / radiotherapy. Thyroid Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395202.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Swartz EE, Belmore K, Decoster LC, Armstrong CW: Emergency face-mask removal effectiveness: a comparison of traditional and nontraditional football helmet face-mask attachment systems. J Athl Train; 2010 Nov-Dec;45(6):560-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PARTICIPANTS: Twenty-five certified athletic trainers.
  • INTERVENTION(S): The independent variable was face-mask attachment system on 5 levels:.
  • [MeSH-major] Athletic Injuries / epidemiology. Facial Injuries / epidemiology. Football / injuries. Head Protective Devices. Spinal Cord Injuries / epidemiology. Sports Medicine


24. Chen SN, Xue YQ, Zhang XG, Wu YF, Pan JL, Wang Y, Cen JN: [Establishment and characterization of a human acute monocytic leukemic cell line, SHI-1, carrying t(6;11)(q27;23) and p53 gene alteration]. Zhonghua Xue Ye Xue Za Zhi; 2005 Feb;26(2):94-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mononuclear cells isolated from the bone marrow of an acute monocytic leukemia (AML-M(5b)) patient at relapse were inoculated in a liquid culture system.
  • The cell line presented typical morphology and immuno-profile of monocytic lineage with the original t(6;11)(q27;q23) and del(17)(p11) abnormalities.
  • A point mutation of ATC-->ACC at exon 6 of the p53 gene was found by sequencing of the PCR products.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921626.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


25. Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M: FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res; 2009 Jun 1;15(11):3680-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.
  • Here, we investigated the potential role of FOXA1 in human thyroid carcinomas.
  • EXPERIMENTAL DESIGN: We examined the level of FOXA1 expression and gene copy number by immunohistochemistry and fluorescence in situ hybridization, respectively, in a cohort of benign and malignant thyroid tumors.
  • In addition, we examined the role of FOXA1 in the proliferation of an undifferentiated thyroid carcinoma cell line by short hairpin RNA-mediated silencing.
  • RESULTS: We show that FOXA1 is overexpressed in human anaplastic thyroid carcinomas (ATC).
  • In addition, we identify FOXA1 DNA copy number gain within the 14q21.1 locus in both an ATC cell line and human ATC cases.
  • Silencing of FOXA1 in an ATC cell line causes G(1) growth arrest and reduction of cell proliferation.
  • CONCLUSIONS: FOXA1 is overexpressed in aggressive thyroid cancers and involved in cell cycle progression in an ATC cell line.
  • Therefore, FOXA1 may be an important oncogene in thyroid tumorigenesis and a potential new therapeutic target for the treatment of anaplastic thyroid cancers.
  • [MeSH-major] Carcinoma / pathology. Hepatocyte Nuclear Factor 3-alpha / metabolism. Oncogene Proteins / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470727.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / FOXA1 protein, human; 0 / Hepatocyte Nuclear Factor 3-alpha; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


26. Zhang W, Shen X, Wang Y, Chen Y, Huang M, Zeng Q, Wei J, Lu Q, Wang G, Deng L, Wang X, Yao K, Yu S, Yang Y: Antibiotic use in five children's hospitals during 2002-2006: the impact of antibiotic guidelines issued by the Chinese Ministry of Health. Pharmacoepidemiol Drug Saf; 2008 Mar;17(3):306-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The Anatomical Therapeutic Chemical Classification/Defined Daily Doses (ATC/DDD) methodology was used.
  • Aggregate data on antibiotic use (ATC code-J01) were expressed in numbers of DDD/100 bed-days for inpatients.
  • CONCLUSIONS: The ATC/DDD methodology proved useful for studying overall antibiotic usage in children's hospitals.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Drug Utilization / statistics & numerical data. Guideline Adherence / statistics & numerical data. Hospitals, Pediatric / statistics & numerical data
  • [MeSH-minor] Adolescent. Cephalosporins / therapeutic use. Child. Child, Preschool. China. Databases, Factual. Female. Humans. Infant. Male. Practice Guidelines as Topic. Practice Patterns, Physicians' / statistics & numerical data. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 John Wiley & Sons, Ltd.
  • (PMID = 18165944.001).
  • [ISSN] 1099-1557
  • [Journal-full-title] Pharmacoepidemiology and drug safety
  • [ISO-abbreviation] Pharmacoepidemiol Drug Saf
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins
  •  go-up   go-down


27. Vanatta LE, Woodruff A, Coleman DE: Comparison of two cryptand separator columns for the determination of trace chloride in semiconductor-grade nitric acid. J Chromatogr A; 2005 Aug 26;1085(1):33-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, the use of a Continuously Regenerated Anion Trap Column (CR-ATC) was evaluated for its ability to purify electrolytically generated eluent.
  • Results also showed that the CR-ATC was necessary for obtaining acceptable acid blanks.

  • Hazardous Substances Data Bank. NITRIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16106844.001).
  • [ISSN] 0021-9673
  • [Journal-full-title] Journal of chromatography. A
  • [ISO-abbreviation] J Chromatogr A
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anion Exchange Resins; 0 / Bicyclo Compounds, Heterocyclic; 0 / Chlorides; 23978-09-8 / cryptating agent 222; 31364-42-8 / cryptating agent 221; 411VRN1TV4 / Nitric Acid
  •  go-up   go-down


28. Zeng Q, Chen G, Vlantis A, Tse G, van Hasselt C: The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J Pathol; 2008 Mar;214(4):425-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas.
  • Oestrogen (E2) is known to promote the proliferation of thyroid papillary carcinoma cells (KAT5).
  • In the study reported herein, the localization of ER alpha (ERalpha) and beta (ERbeta) in KAT5 and anaplastic carcinoma cells (FRO) was studied by immunofluorescence staining and by immunoblotting the proteins in subcellular fractions.
  • The pattern of the subcellular localization of ERalpha and ERbeta differed between papillary and anaplastic cancer.
  • Upon E2 treatment, the level of ERalpha increased in the nuclei of papillary cancer cells but ERbeta remained unchanged.
  • The level of mitochondrial ERbeta surpassed that of ERalpha in anaplastic cancer cells.
  • The different locations of ERalpha and ERbeta in KAT5 and FRO agreed with the finding that E2 promoted the proliferation of KAT5 but inhibited or did not affect that of FRO cells, and with the proposed functions of these two receptors.
  • E2 inhibited the level of Bax in the mitochondria of papillary cancer, followed by a decrease of cytochrome c and/or apoptosis-inducing factor (AIF) release from the mitochondria into the cytosol.
  • However, in anaplastic cancer, E2 promoted the expression of Bax in the mitochondria and the release of cytochrome c and/or AIF from mitochondria into the cytosol.
  • Our results may explain the differences in epidemiology and responses to anti-tumour therapy between papillary and anaplastic cancer in terms of the subcellular localization of ER isoforms.
  • In conclusion, the findings provide evidence to support the observation that E2 is an important factor in the development of thyroid cancer.
  • The subcellular localization of ERalpha and ERbeta may account for the different pathogenesis of thyroid papillary and anaplastic cancers.
  • [MeSH-major] Carcinoma / metabolism. Carcinoma, Papillary / metabolism. Receptors, Estrogen / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. FULVESTRANT .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085520.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AIFM1 protein, human; 0 / Apoptosis Inducing Factor; 0 / Estrogen Antagonists; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / bcl-2-Associated X Protein; 22X328QOC4 / fulvestrant; 4TI98Z838E / Estradiol; 9007-43-6 / Cytochromes c
  •  go-up   go-down


29. Cohen JD, Shapiro M, Grozovski E, Lev S, Fisher H, Singer P: Extubation outcome following a spontaneous breathing trial with automatic tube compensation versus continuous positive airway pressure. Crit Care Med; 2006 Mar;34(3):682-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extubation outcome following a spontaneous breathing trial with automatic tube compensation versus continuous positive airway pressure.
  • OBJECTIVE: We hypothesized that the additional use of automatic tube compensation (ATC) during a spontaneous breathing trial with continuous positive airway pressure (CPAP), by minimizing respiratory work, would result in more patients undergoing successful extubation.
  • INTERVENTIONS: Patients were randomized to undergo a 1-hr spontaneous breathing trial with either ATC with CPAP (ATC group, n=51) or CPAP alone (CPAP group, n=48).
  • ATC was provided by commercially available mechanical ventilators.
  • There was a trend for more patients in the ATC group to tolerate the breathing trial and undergo extubation (96% vs. 85%; p=.08).
  • The rate of reintubation was 14% in the ATC group and 24% in the CPAP group (p=.28).
  • Significantly more patients in the ATC group thus met the criteria for successful extubation (82% vs. 65%; p=0.04).
  • CONCLUSION: This is the largest single-center study to date assessing the use of commercially available ATC and suggests that this might be a useful mode for performing a spontaneous breathing trial preceding extubation in a general intensive care population.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2006 Nov;34(11):2867; author reply 2867 [17053584.001]
  • (PMID = 16505653.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


30. Tomoda C, Moatamed F, Naeim F, Hershman JM, Sugawara M: Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood); 2008 Nov;233(11):1433-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.
  • Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), has been reported to inhibit the growth of medullary thyroid carcinoma (MTC) cells in vitro.
  • Indomethacin inhibited cell growth of all three MTC cell lines but not normal thyroid cells or anaplastic thyroid carcinoma cells.
  • Indomethacin at 25 muM, a putative therapeutic serum indomethacin level, showed potency similar to 100 to 200 nM sunitinib, a receptor tyrosine kinase inhibitor.
  • Since no drug therapy is currently available for MTC, indomethacin may be one of the therapeutic candidates.
  • [MeSH-major] Carcinoma, Medullary / pathology. Cell Cycle / drug effects. Cell Proliferation / drug effects. Cyclooxygenase Inhibitors / pharmacology. Indomethacin / pharmacology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • Hazardous Substances Data Bank. Calcitonin .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791128.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Cyclooxygenase Inhibitors; 0 / Indoles; 0 / Pyrroles; 0 / Retinoblastoma Protein; 0 / sunitinib; 9007-12-9 / Calcitonin; K7Q1JQR04M / Dinoprostone; XXE1CET956 / Indomethacin
  •  go-up   go-down


31. Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Müller GA, Mössner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler JG: Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer; 2008 May 6;98(9):1525-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trastuzumab (Herceptin) has improved therapy of breast cancer.
  • We used a mouse model that allows anhydrotetracycline (ATc)-controlled downregulation of ERBB2 in tumour tissue.
  • Surprisingly, trastuzumab caused a much weaker effect compared to ATc-induced ERBB2 downregulation, although a decrease in ERBB2 membrane localisation was induced.
  • The suboptimal effect of trastuzumab compared to the maximally possible effect induced by ATc demonstrates a high potential for improved ERBB2 blocking therapies.

  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):603-12 [17100566.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4744-9 [11406546.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4132-41 [12124352.001]
  • [Cites] Mol Cancer Ther. 2002 Jul;1(9):707-17 [12479367.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):756-60 [12610629.001]
  • [Cites] Curr Opin Chem Biol. 2003 Aug;7(4):490-5 [12941424.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7221-31 [14612517.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] Cancer Res. 1990 Mar 1;50(5):1550-8 [1689212.001]
  • [Cites] Cell. 1990 Apr 20;61(2):203-12 [2158859.001]
  • [Cites] J Biol Chem. 1991 Aug 5;266(22):14300-5 [1677643.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5547-51 [1319065.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):737-44 [8622019.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):901-11 [8806679.001]
  • [Cites] J Drug Target. 2004;12(7):461-71 [15621671.001]
  • [Cites] Clin Breast Cancer. 2005 Aug;6(3):240-6 [16137435.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Mol Carcinog. 2006 May;45(5):302-8 [16496387.001]
  • [Cites] Science. 2006 May 26;312(5777):1175-8 [16728632.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2619-21 [16775247.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Jun;6(4):333-63 [16848724.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):199-208 [16850126.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3735-46 [16847284.001]
  • [Cites] Breast Cancer. 2006;13(3):236-48 [16929116.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1534-41 [16887935.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • (PMID = 18454161.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Tetracyclines; 680VDL31MX / 4-epianhydrotetracycline; 9007-43-6 / Cytochromes c; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / 3-Phosphoinositide-Dependent Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2391101
  •  go-up   go-down


32. Yard EE, Schroeder MJ, Fields SK, Collins CL, Comstock RD: The epidemiology of United States high school soccer injuries, 2005-2007. Am J Sports Med; 2008 Oct;36(10):1930-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Soccer-related injury data were collected over the 2005-2006 and 2006-2007 school years from 100 nationally representative United States high schools via Reporting Information Online (RIO, an Internet-based sports-related injury surveillance system).
  • RESULTS: Participating certified athletic trainers reported 1524 soccer injuries during 637 446 athlete exposures (AEs), for an injury rate of 2.39 per 1000 AEs, corresponding to a nationally estimated 807 492 soccer-related injuries during the 2005-2006 and 2006-2007 seasons.
  • [MeSH-major] Athletic Injuries / epidemiology. Soccer / injuries

  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628486.001).
  • [ISSN] 1552-3365
  • [Journal-full-title] The American journal of sports medicine
  • [ISO-abbreviation] Am J Sports Med
  • [Language] eng
  • [Grant] United States / PHS HHS / / R49/ CEOOO674-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


33. Njim L, Moussa A, Hadhri R, Gassab I, Ben Yahia N, Mahmoudi H, Zakhama A: [Angiomatoid tumor of the thyroid gland: primitive angiosarcoma or variant of anaplastic carcinoma?]. Ann Pathol; 2008 Jun;28(3):221-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiomatoid tumor of the thyroid gland: primitive angiosarcoma or variant of anaplastic carcinoma?].
  • [Transliterated title] Tumeur angiomatoïde de la thyroïde: angiosarcome primitif ou variante du carcinome anaplasique?
  • Thyroid gland angiomatoid tumors are an extremely aggressive neoplasms with varied histological patterns and features of endothelial differentiation.
  • The histogenesis of thyroid angiomatoid tumors has been controversial for many years: these tumors may be either a variant of anaplastic carcinoma, or an angiosarcoma.
  • We report a case of thyroid angiomatoid tumor in a 68-year-old woman.
  • We also discuss, through a review of the literature, the pathologic criteria that could be used to distinguish between angiosarcoma and anaplastic carcinoma of the thyroid.
  • [MeSH-major] Carcinoma / pathology. Hemangiosarcoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Keratins / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706366.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


34. Lee EB, Kim JY, Zhao J, Park MH, Song YW: Haplotype association of IL-8 gene with Behcet's disease. Tissue Antigens; 2007 Feb;69(2):128-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haplotype association of IL-8 gene with Behcet's disease.
  • Interleukin-8 (IL-8), a CXC chemokine that recruits and activates inflammatory cells, plays a critical role in the pathogenesis of Behcet's disease (BD).
  • However, the frequency of haplotype TAT inferred from SNPs, IL-8 -353 A/T, -251 A/T and +678 T/C, was significantly higher in patients with BD than controls (5.9 vs 0.0%, P = 0.0001), as was haplotype ATC (6.7 vs 0.0%, P < 0.0001).

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257314.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / HLA-B51 Antigen; 0 / Interleukin-8; 0 / Receptors, Interleukin-8A; 0 / Receptors, Interleukin-8B
  •  go-up   go-down


35. Stedmon AW, Sharples S, Littlewood R, Cox G, Patel H, Wilson JR: Datalink in air traffic management: Human factors issues in communications. Appl Ergon; 2007 Jul;38(4):473-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a novel air traffic control (ATC) task, two experiments are reported.

  • MedlinePlus Health Information. consumer health - Ergonomics.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506976.001).
  • [ISSN] 0003-6870
  • [Journal-full-title] Applied ergonomics
  • [ISO-abbreviation] Appl Ergon
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


41. Zitzelsberger H, Thomas G, Unger K: Chromosomal aberrations in thyroid follicular-cell neoplasia: in the search of novel oncogenes and tumour suppressor genes. Mol Cell Endocrinol; 2010 May 28;321(1):57-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations in thyroid follicular-cell neoplasia: in the search of novel oncogenes and tumour suppressor genes.
  • Thyroid cancer derived from the follicular cell is characterised by specific gene alterations that are closely linked to the various pathological types comprising papillary, follicular and anaplastic thyroid cancer.
  • This situation, coupled with the demonstration of genetic heterogeneity in thyroid cancer, is a strong motivation for the search of novel gene alterations.
  • Chromosomal aberrations are a good starting point to initiate this search and therefore the current knowledge on chromosomal alterations in thyroid follicular-cell neoplasia is reviewed in this article.
  • The identification of novel genetic markers in thyroid cancer will be further improved by integrative approaches combining data from genomic and expression analyses with clinical data.
  • This approach is powerful to identify genetic markers as well as new therapeutic targets in follicular-cell thyroid cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Chromosome Aberrations. Genes, Tumor Suppressor. Oncogenes / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19961897.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 110
  •  go-up   go-down


42. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT: Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol; 2005 Jan;18(1):48-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors.
  • The diagnosis of thyroid tumors is critical for clinical management; however, tumors with follicular architecture often present problems.
  • We evaluated the diagnostic use of the protein expression of four genes that were found to be upregulated in papillary thyroid carcinoma compared to normal thyroid (LGALS3, FN1, CITED1 and KRT19), and of the mesothelial cell surface protein recognized by monoclonal antibody HBME1 in thyroid tumors.
  • Tissues from 85 carcinomas (67 papillary, six follicular, eight Hürthle cell and four anaplastic) and 21 adenomas were evaluated by immunohistochemistry for the expression of these gene protein products, for example, galectin-3 (GAL3), fibronectin-1 (FN1), CITED1, cytokeratin-19 (CK19) and HBME1.
  • The expression of all five proteins was significantly associated with malignancy, and highly specific (> or = 90%) for carcinoma compared to adenoma.
  • GAL3, FN1 and/or HBME1 expression was seen in 100% of carcinomas (85/85) and in 24% of adenomas (5/21).
  • Coexpression of multiple proteins was seen in 95% of carcinomas and only 5% of adenomas (P<0.0001).
  • Coexpression of FN1 and GAL3 (FN1+ GAL3+, 70/85) or FN1 and HBME1 (FN1+ HBME1+, 53/85) was restricted to carcinomas, while their concurrent absence (FN1- GAL3- or FN1- HBME1-, 18/21 adenoma) was highly specific (96%) for benign lesions.
  • Among non-neoplastic thyroids, adenomatous hyperplasia frequently expressed GAL3 (n=16), CK19 (n=9) and CITED1 (n=7), but the expression was predominantly focal in contrast to the diffuse expression in carcinomas.
  • An immunohistochemical panel consisting of GAL3, FN1 and HBME1 may be useful in the diagnosis of follicular cell-derived thyroid tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Diagnosis, Differential. Fibronectins / analysis. Galectin 3 / analysis. Humans. Immunohistochemistry. Keratins / analysis. Nuclear Proteins. Statistics as Topic. Trans-Activators / analysis. Transcription Factors

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15272279.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00034
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CITED1 protein, human; 0 / Fibronectins; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Nuclear Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 68238-35-7 / Keratins
  •  go-up   go-down


43. Närhi U, Vanakoski J, Sihvo S: Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects. Clin Drug Investig; 2005;25(4):243-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the consumption of H(2)-receptor antagonists, proton pump inhibitors, sucralfate and antacids (A02BA, A02BC, A02BX02 and A02A, respectively, according to the Anatomical Therapeutic Chemical [ATC] classification).
  • RESULTS: The total consumption of medicines for the treatment of peptic ulcer disease and gastro-oesophageal reflux disease increased more than 2-fold from 1990 to 2003 (from 12.8 daily defined doses [DDD]/1000 inhabitants/day to 29.6 DDD/1000 inhabitants/day).
  • Since 1998, proton pump inhibitors have been the most commonly used drug group for the treatment of peptic ulcer and gastro-oesophageal reflux disease in Finland.
  • In 2003, the consumption of proton pump inhibitors was 75% (22.2 DDD/1000 inhabitants/day) of the total consumption of drugs for the treatment of peptic ulcer and gastro-oesophageal reflux disease.
  • However, the total number of reports concerning these ATC groups in the national ADR database is not very high, and therefore patient-based surveys are needed to verify this finding.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Toxicol. 1991 Oct;69(4):253-8 [1683484.001]
  • [Cites] Scand J Gastroenterol. 1997 Sep;32(9):855-61 [9299660.001]
  • (PMID = 17523774.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


44. Knopf H: [Medicine use in children and adolescents. Data collection and first results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 May-Jun;50(5-6):863-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most frequently, the boys and girls used medicines for the treatment of respiratory tract conditions (ATC code R00: 16.8%).
  • This was followed by Alimentary System and Metabolism (ATC code A00: 16.0%) and Dermatological Preparations (ATC code D00: 9.7%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17514472.001).
  • [ISSN] 1436-9990
  • [Journal-full-title] Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
  • [ISO-abbreviation] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Rapkiewicz A, Roses D, Goldenberg A, Levine P, Bannan M, Simsir A: Encapsulated anaplastic thyroid carcinoma transformed from follicular carcinoma: a case report. Acta Cytol; 2009 May-Jun;53(3):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Encapsulated anaplastic thyroid carcinoma transformed from follicular carcinoma: a case report.
  • BACKGROUND: Anaplastic thyroid carcinoma (ATC) is rare but is one of the most aggressive and lethal human malignancies.
  • Cytologically, ATC has a variable morphologic appearance, including squamoid, giant, spindled and pleomorphic cells.
  • The coexistence of ATC and differentiated or poorly differentiated thyroid carcinoma has been described and usually is diagnosed when the disease is locally advanced.
  • CASE: We describe a case of surgically resectable, encapsulated, well-circumscribed ATC occurring in association with a better differentiated follicular carcinoma diagnosed by fine needle aspiration in a patient exposed to external ionizing radiation.
  • CONCLUSION: Encapsulated variants of anaplastic carcinoma can be seen in association with lower grade thyroid carcinoma such as follicular carcinoma.
  • Accurate diagnosis is dependent on adequate sampling.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma / secondary. Cell Transformation, Neoplastic. Chernobyl Nuclear Accident. Neoplasms, Radiation-Induced / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534279.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


47. Falco CE, Grande AM, Nicolardi S, Viganò M, Benazzo M: Management of anaplastic thyroid carcinoma spread over the trachea with mediastinal extension. G Chir; 2010 Aug-Sep;31(8-9):390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anaplastic thyroid carcinoma spread over the trachea with mediastinal extension.
  • INTRODUCTION: We report a case of treatment of anaplastic thyroid carcinoma spread over the trachea with mediastinal extension.
  • METHODS: Case report and review of the world literature concerning the treatment of anaplastic thyroid carcinoma are presented.
  • DISCUSSION: The role of surgery in treatment of anaplastic carcinoma remains controversial.
  • Our case we underlined two questions: the appropriateness of the surgery options with extra-thyroid spread and the better surgery approach to anaplastic thyroid carcinoma interesting the mediastinum controlling the great vessels of the neck.
  • Even if complete resection cannot be achieved, surgical resection can immediately reduce the tumour bulk and achieve good local control of the disease to avoid the palliative tracheotomy.
  • [MeSH-major] Carcinoma / surgery. Mediastinal Neoplasms / surgery. Sternotomy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery. Tracheal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843444.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


48. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf); 2005 Nov;63(5):588-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
  • BACKGROUND: The BRAF(V600E) mutation, the most common genetic alteration reported in papillary thyroid carcinoma, has been associated with poor prognostic factors.
  • AIM: To determine whether the presence of the BRAF(V600E) mutation is associated with poor prognosis in Korean patients with conventional papillary thyroid microcarcinoma (micro-PTC).
  • PATIENTS AND METHODS: DNA was extracted from paraffin-embedded thyroid tumour specimens taken from 60 patients with conventional micro-PTC, as well as from nine patients with follicular variant papillary carcinoma, six with nodular hyperplasia, four with follicular carcinoma (including one with Hürthle cell carcinoma), four with follicular adenoma (including two with Hürthle cell adenoma) and one each with medullary carcinoma, poorly differentiated carcinoma and anaplastic carcinoma.
  • RESULTS: The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types of thyroid tumours.
  • [MeSH-major] Adenoma / genetics. Point Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16268813.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


49. Schubert I, Köster I, Lehmkuhl G: The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int; 2010 Sep;107(36):615-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.
  • BACKGROUND: The goal of this study is to assess changes in the prevalence of attention-deficit/hyperactivity disorder (ADHD) and methylphenidate prescriptions over the period 2000 to 2007 on the basis of data from a German statutory health insurance carrier.
  • Per calender year, 50,000 to 63,000 children and adolescents were retrospectively observed with respect to the documentation of ADHD diagnosis (ICD-10 diagnosis F90) and the prescribing of methylphenidate (ATC: N06BA04).
  • [MeSH-major] Attention Deficit Disorder with Hyperactivity / drug therapy. Attention Deficit Disorder with Hyperactivity / epidemiology. Central Nervous System Stimulants / therapeutic use. Methylphenidate / therapeutic use

  • Genetic Alliance. consumer health - Attention Deficit Disorder.
  • MedlinePlus Health Information. consumer health - Attention Deficit Hyperactivity Disorder.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychiatr Serv. 2008 May;59(5):554-60 [18451016.001]
  • [Cites] Psychiatr Serv. 2009 Feb;60(2):269 [19176429.001]
  • [Cites] Prax Kinderpsychol Kinderpsychiatr. 2009;58(3):170-85 [19435152.001]
  • [Cites] Gesundheitswesen. 2004 Jun;66(6):387-92 [15206042.001]
  • [Cites] Eur J Clin Pharmacol. 2004 Jul;60(5):377-9 [15168100.001]
  • [Cites] Z Kinder Jugendpsychiatr Psychother. 2004 Jul;32(3):157-66 [15357012.001]
  • [Cites] J Child Adolesc Psychopharmacol. 2005 Feb;15(1):62-7 [15741787.001]
  • [Cites] Gesundheitswesen. 2005 Aug-Sep;67(8-9):638-45 [16217718.001]
  • [Cites] Am J Psychiatry. 2006 Apr;163(4):579-85 [16585430.001]
  • [Cites] Clin Drug Investig. 2006;26(3):161-7 [17163247.001]
  • [Cites] Aust N Z J Public Health. 2007 Apr;31(2):120-6 [17461001.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):827-35 [17514469.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):871-8 [17514473.001]
  • [Cites] Gesundheitswesen. 2007 May;69(5):292-6 [17582546.001]
  • [Cites] Tidsskr Nor Laegeforen. 2007 Sep 20;127(18):2360-2 [17895938.001]
  • [Cites] Rev Epidemiol Sante Publique. 2007 Oct;55(5):357-63 [17889474.001]
  • [Cites] Laeknabladid. 2007 Dec;93(12):825-32 [18057472.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2007 Oct;16(7):430-8 [17468967.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Mar;64(3):311-7 [18026941.001]
  • [Cites] Psychiatr Serv. 2008 May;59(5):507-14 [18451006.001]
  • [CommentIn] Dtsch Arztebl Int. 2010 Dec;107(51-52):919; author reply 919-20 [21249142.001]
  • (PMID = 20948775.001).
  • [ISSN] 1866-0452
  • [Journal-full-title] Deutsches Ärzteblatt international
  • [ISO-abbreviation] Dtsch Arztebl Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  • [Other-IDs] NLM/ PMC2947846
  •  go-up   go-down


50. van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT: Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands. Eur J Clin Pharmacol; 2008 Oct;64(10):1013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: From the Dutch Interaction Database (IADB.nl) we selected children aged 0-19 years who received at least one prescription for an AED (ATC-code beginning with N03A) between 1997 and 2005.
  • The 50% survival probability (= time period when 50% of children had stopped using AEDs) was around 2 years, with a significantly lower discontinuation of treatment for girls than boys (P = 0.04).
  • [MeSH-major] Anticonvulsants / therapeutic use. Epilepsy / drug therapy
  • [MeSH-minor] Carbamazepine / administration & dosage. Carbamazepine / adverse effects. Carbamazepine / therapeutic use. Child. Databases, Factual. Drug Utilization. Female. Humans. Incidence. Male. Netherlands / epidemiology. Practice Guidelines as Topic. Prevalence. Retrospective Studies. Triazines / administration & dosage. Triazines / adverse effects. Triazines / therapeutic use. Valproic Acid / administration & dosage. Valproic Acid / adverse effects. Valproic Acid / therapeutic use

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. LAMOTRIGINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2004 Aug;127(Pt 8):1774-84 [15201192.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 Mar;13(3):173-9 [15072117.001]
  • [Cites] Br J Clin Pharmacol. 2006 Dec;62(6):660-5 [16796700.001]
  • [Cites] Acta Neurol Scand. 2006 Jun;113(6):405-11 [16674607.001]
  • [Cites] BMJ. 1997 Jan 18;314(7075):180-1 [9022432.001]
  • [Cites] Br J Clin Pharmacol. 2007 Jun;63(6):689-97 [17257162.001]
  • [Cites] Neurology. 2004 Apr 27;62(8):1252-60 [15111659.001]
  • [Cites] Psychiatr Serv. 2006 May;57(5):681-5 [16675763.001]
  • [Cites] N Engl J Med. 1999 Aug 12;341(7):485-9 [10441604.001]
  • [Cites] Acta Neurol Scand. 2001 Jul;104(1):6-11 [11442436.001]
  • [Cites] Eur J Paediatr Neurol. 2006 May;10(3):107-13 [16638642.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):239-47 [15719354.001]
  • [Cites] Neurology. 2006 Mar 28;66(6 Suppl 3):S37-45 [16567741.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):44-50 [7823066.001]
  • [Cites] Epilepsia. 2002 Nov;43(11):1402-9 [12423392.001]
  • (PMID = 18618103.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Triazines; 33CM23913M / Carbamazepine; 614OI1Z5WI / Valproic Acid; U3H27498KS / lamotrigine
  •  go-up   go-down


51. Lewandowski W, Matsakis D, Panfilo G, Tavella P: Analysis of correlations, and link and equipment noise in the uncertainties of [UTC - UTC(k)]. IEEE Trans Ultrason Ferroelectr Freq Control; 2008 Apr;55(4):750-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of correlations, and link and equipment noise in the uncertainties of [UTC - UTC(k)].
  • We refine our estimate of the uncertainty in [UTC - UTC(k)] by taking into account the contribution of correlations between the links.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467219.001).
  • [ISSN] 0885-3010
  • [Journal-full-title] IEEE transactions on ultrasonics, ferroelectrics, and frequency control
  • [ISO-abbreviation] IEEE Trans Ultrason Ferroelectr Freq Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Wagstaff AS, Arva P: Hearing loss in civilian airline and helicopter pilots compared to air traffic control personnel. Aviat Space Environ Med; 2009 Oct;80(10):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: In order to investigate possible hearing loss as a consequence of aviation noise, a comparative analysis of audiometric data from Norwegian Air Traffic Control (ATC) personnel, airline (fixed-wing) pilots, and helicopter pilots was performed.
  • METHODS: Male ATC, airline, and helicopter pilots were selected randomly from the Civil Aviation Authority (CAA) medical files.
  • There were 182 subjects included in the study: 50, 81, and 51 subjects for ATC, helicopter, and airline pilots, respectively.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817237.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Datta C, Bhattacharyya S, Ghosh A, Ghosh S: Dedifferentiated papillary carcinoma of thyroid in an adolescent girl--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):496-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated papillary carcinoma of thyroid in an adolescent girl--a case report.
  • Dedifferentiated papillary carcinoma of thyroid shows combined histopathological features of classical papillary carcinoma and anaplastic carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366108.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


54. Fedele M, Fidanza V, Battista S, Pentimalli F, Klein-Szanto AJ, Visone R, De Martino I, Curcio A, Morisco C, Del Vecchio L, Baldassarre G, Arra C, Viglietto G, Indolfi C, Croce CM, Fusco A: Haploinsufficiency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res; 2006 Mar 1;66(5):2536-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, blockage of HMGA1 synthesis prevents rat thyroid cell transformation by murine transforming retroviruses, and an adenovirus carrying the HMGA1 gene in the antisense orientation induces apoptotic cell death in anaplastic human thyroid carcinoma cell lines, but not in normal thyroid cells.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510570.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Interleukins; 0 / Rag2 protein, mouse; 124544-67-8 / HMGA1a Protein; 128559-51-3 / RAG-1 protein
  •  go-up   go-down


55. Al-Watban FA, Zhang XY: Photodynamic therapy of human undifferentiated thyroid carcinoma-bearing nude mice using topical 5-aminolevulinic acid. Photomed Laser Surg; 2005 Apr;23(2):206-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of human undifferentiated thyroid carcinoma-bearing nude mice using topical 5-aminolevulinic acid.
  • OBJECTIVE: We determined and evaluated the effect of photodynamic therapy (PDT) using topical 5-aminolevulinic acid (ALA) cream in treating human undifferentiated thyroid carcinoma (UTC)-bearing nude mice.
  • BACKGROUND DATA: UTC constitutes almost 10% of thyroid cancers and shows a very poor response to chemotherapy.
  • MATERIALS AND METHODS: UTC tumor was implanted in the right flank of the nude mice after anesthesia.
  • CONCLUSIONS: PDT is effective in delaying the growth of UTC-bearing nude mice using topical ALA cream and laser light with inappropriate parameters.
  • [MeSH-major] Aminolevulinic Acid / pharmacology. Carcinoma / therapy. Photochemotherapy. Photosensitizing Agents / pharmacology. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910188.001).
  • [ISSN] 1549-5418
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


56. Fernandez NJ, Clark EG, Larson VS: What is your diagnosis? Ventral neck mass in a dog. Vet Clin Pathol; 2008 Dec;37(4):447-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is your diagnosis? Ventral neck mass in a dog.
  • On physical examination, numerous abnormalities were found, including a large ventral neck mass (100 cm(3)) in the area of the thyroid gland.
  • Fine-needle aspirates revealed 2 apparent populations of cells: one suspected to be a well-differentiated thyroid carcinoma, and the other consisting of large pleomorphic to spindloid cells suggestive of sarcoma.
  • A section of the mass was evaluated histologically and a diagnosis of anaplastic thyroid carcinoma was made.
  • Immunohistochemical evaluation with antibodies to thyroglobulin, cytokeratin, and vimentin confirmed distinct populations of malignant epithelial and malignant mesenchymal cells, and the diagnosis was amended to thyroid carcinosarcoma.
  • Thyroid carcinosarcoma is a rare neoplasm in dogs in which the cell type comprising the mesenchymal component can vary.
  • Immunochemistry to demonstrate the 2 cell types may be necessary to differentiate thyroid carcinosarcoma from anaplastic thyroid carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19055583.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Koussis H, Maruzzo M, Scola A, Ide EC, Fassina A, Marioni G, Lora O, Corti L, Karachontziti P, Jirillo A: A case of anaplastic thyroid cancer with long-term survival. Anticancer Res; 2010 Apr;30(4):1273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic thyroid cancer with long-term survival.
  • Anaplastic thyroid carcinoma (ATC) (less than 10% of all thyroid cancer) is a high-grade neoplasm, characterized by an aggressive clinical course and refractoriness to currently available local and systemic modalities of treatment.
  • It is considered the most aggressive solid tumour, there is no adequate therapy for this disease and few patients with ATC live more than 1 year following diagnosis.
  • We report herein an unusual case of ATC in a 59-year-old woman.
  • She received many kinds of chemotherapeutical and multimodal treatment; we obtained a long period of localized disease (about two years) and an excellent response to therapy.
  • She is still alive 58 months from diagnosis.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy


58. Aguilar G, Jover JL, Soro M, Belda FJ, García-Raimundo M, Maruenda A: Additional work of breathing and breathing patterns in spontaneously breathing patients during pressure support ventilation, automatic tube compensation and amplified spontaneous pattern breathing. Eur J Anaesthesiol; 2005 Apr;22(4):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional work of breathing and breathing patterns in spontaneously breathing patients during pressure support ventilation, automatic tube compensation and amplified spontaneous pattern breathing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892412.001).
  • [ISSN] 0265-0215
  • [Journal-full-title] European journal of anaesthesiology
  • [ISO-abbreviation] Eur J Anaesthesiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Letter
  • [Publication-country] England
  •  go-up   go-down


59. Takarabe M, Okuda S, Itoh M, Tokimatsu T, Goto S, Kanehisa M: Network analysis of adverse drug interactions. Genome Inform; 2008;20:252-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We defined drug target and drug-metabolizing enzymes as interaction factors using information on them in KEGG DRUG, and classified drugs into pharmacological/chemical subgroups.
  • To characterize other interactions without interaction factors, we used the ATC classification system and found an association between interaction mechanisms and pharmacological/chemical subgroups.

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19425139.001).
  • [ISSN] 0919-9454
  • [Journal-full-title] Genome informatics. International Conference on Genome Informatics
  • [ISO-abbreviation] Genome Inform
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations; 0 / Receptors, Biogenic Amine; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


60. Hassan I, Wunderlich A, Slater E, Hoffmann S, Celik I, Zielke A: Antisense p53 decreases production of VEGF in follicular thyroid cancer cells. Endocrine; 2006 Jun;29(3):409-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense p53 decreases production of VEGF in follicular thyroid cancer cells.
  • Inactivating mutations of wild-type p53 (WTp53) tumor suppressor gene are common in anaplastic thyroid cancer (ATC) and are associated with poor prognosis.
  • Therefore, the potential of MTp53 knockout by oligodeoxyribonucleotide phosphorothioates (ODNs) to affect VEGF production of undifferentiated thyroid cancer cells with a recessive MTp53 mutation was evaluated.
  • Transfection of undifferentiated thyroid cancer cells with ODN reduced VEGF secretion of FTC-133 cells following transfection by 34% as compared to the negative control (cells transfected with ODN-HIV; p = 0.03).
  • These results suggest that transient MTp53 knockout with ODNs complementary to p53 nucleotide sequences impair secretion of VEGF in the undifferentiated thyroid cancer cell line FTC-133.
  • [MeSH-major] Adenocarcinoma, Follicular / metabolism. Gene Silencing / physiology. Thyroid Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Thyroid cancer, follicular.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1997 Sep;66(1):11-8 [9290687.001]
  • [Cites] Anticancer Res. 2000 Jul-Aug;20(4):2723-8 [10953350.001]
  • [Cites] Thyroid. 2002 Nov;12(11):953-61 [12490072.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1582-4 [7521539.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):467-73 [2416426.001]
  • [Cites] Langenbecks Arch Surg. 1998 Aug;383(3-4):269-75 [9776455.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3668-72 [9768682.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3741-7 [9360534.001]
  • [Cites] Leuk Lymphoma. 1994 Jan;12(3-4):223-31 [8167553.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):671-7 [10934169.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Science. 2002 Feb 22;295(5559):1526-8 [11859195.001]
  • [Cites] Science. 1993 Aug 20;261(5124):1004-12 [8351515.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6139-45 [15579770.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3498-504 [8855792.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6161-5 [8521408.001]
  • [Cites] Ann Clin Lab Sci. 2003 Spring;33(2):192-9 [12817624.001]
  • [Cites] Horm Res. 1997;47(4-6):145-57 [9167946.001]
  • (PMID = 16943578.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides, Antisense; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


61. McCrory P, Meeuwisse W, Johnston K, Dvorak J, Aubry M, Molloy M, Cantu R: Consensus statement on concussion in sport - the Third International Conference on Concussion in Sport held in Zurich, November 2008. Phys Sportsmed; 2009 Jun;37(2):141-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This document is developed for use by physicians, therapists, certified athletic trainers, health professionals, coaches and other people involved in the care of injured athletes, whether at the recreational, elite, or professional level.
  • [MeSH-major] Athletic Injuries. Brain Concussion

  • MedlinePlus Health Information. consumer health - Concussion.
  • MedlinePlus Health Information. consumer health - Sports Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048521.001).
  • [ISSN] 0091-3847
  • [Journal-full-title] The Physician and sportsmedicine
  • [ISO-abbreviation] Phys Sportsmed
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


62. Lin JD, Chao TC: Follicular thyroid carcinoma: From diagnosis to treatment. Endocr J; 2006 Aug;53(4):441-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular thyroid carcinoma: From diagnosis to treatment.
  • Unusual presentations with bone, lung or soft tissue metastases in initial diagnosis of follicular thyroid carcinoma have been reported occasionally.
  • This implies how difficult it is to diagnosis this type of cancer at the pre-operative or intra-operative stage of treatment.
  • Fine needle aspiration cytology has been shown to be an ineffective method for diagnosing vascular or capsule invasion of follicular thyroid cancer.
  • Clinical application of various gene expressions in thyroid follicular tumors by needle aspiration using in situ hybridization requires further investigation.
  • Although radioactive iodide (131I) has been used as the standard treatment for follicular thyroid carcinoma with distant metastases, the effectiveness of 131I treatment for follicular thyroid carcinoma depends on the differentiation of cancer cells.
  • The possibility of 131I for thyroid remnant ablation replacing a secondary operation for follicular thyroid carcinoma has been debated.
  • Recent studies applied more expressions of sodium iodide symporters to attain the effect of 131I treatment and slow the proliferation of thyroid cancer cell which, in turn, slows the progression of follicular carcinoma.
  • Consensus for the surgical procedures for the specific prognostic risks for follicular thyroid carcinoma is needed.
  • Dedifferentiated, anti-angiogenic, or gene therapies for follicular thyroid cancer with distant metastases or anaplastic transformation comprise the principal directions in future research for this cancer.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / therapy. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Diagnostic Imaging. Humans. Iodine Radioisotopes / therapeutic use. Predictive Value of Tests. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807500.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes
  • [Number-of-references] 72
  •  go-up   go-down


63. Sun F, Sun Y, Yu Z, Zhang D, Zhang J, Song B, Zheng H: Interleukin-10 gene polymorphisms influence susceptibility to cachexia in patients with low-third gastric cancer in a Chinese population. Mol Diagn Ther; 2010 Apr 01;14(2):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-10 gene polymorphisms influence susceptibility to cachexia in patients with low-third gastric cancer in a Chinese population.
  • Therefore, we designed this study to investigate whether polymorphisms of the IL10 gene were associated with cachexia in patients with low-third gastric cancer in a Chinese population.
  • METHODS: 190 patients with low-third gastric cancer were included in this study.
  • In a logistic regression analysis adjusted for actual weight and carcinoma stage, the -1082AG genotype was associated with an odds ratio (OR) of 2.45 (95% CI 1.21, 4.96; p = 0.01), and the -819CC genotype was associated with an OR of 3.70 (95% CI 1.20, 11.39; p = 0.02) for cachexia.
  • Furthermore, haplotype analysis of the -1082A/G, -819T/C, and -592A/C SNPs revealed that at least five haplotypes (ATA, ACC, GCC, ACA, and ATC) were present in this Chinese population, and the -1082G/-819C/-592C (GCC) haplotype was associated with a significantly increased risk of cachexia as compared with the ATA haplotype (OR = 2.42; 95% CI 1.17, 5.00; p = 0.02).
  • CONCLUSION: Our results indicate that genetic polymorphisms of IL-10 may influence susceptibility to cachexia in patients with low-third gastric cancer in this Chinese population.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Cachexia / complications. Cachexia / genetics. Genetic Predisposition to Disease. Interleukin-10 / genetics. Polymorphism, Single Nucleotide / genetics. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 1999 Aug;30(2):526-30 [10421663.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2006 Sep;9(5):603-6 [16912557.001]
  • [Cites] J Infect Dis. 2009 Feb 1;199(3):451-4 [19099482.001]
  • [Cites] Immunogenetics. 2003 Mar;54(12):896-9 [12671741.001]
  • [Cites] J Dermatol Sci. 2005 Feb;37(2):111-3 [15659329.001]
  • [Cites] Eur J Immunogenet. 1997 Feb;24(1):1-8 [9043871.001]
  • [Cites] Am J Clin Nutr. 2009 Apr;89(4):1164-72 [19244371.001]
  • [Cites] Support Care Cancer. 2008 Mar;16(3):229-34 [18071761.001]
  • [Cites] Eur J Immunogenet. 2002 Jun;29(3):237-40 [12047360.001]
  • [Cites] Nutrition. 2005 Sep;21(9):977-85 [16043325.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):617-23 [12594817.001]
  • [Cites] J Leukoc Biol. 2005 Nov;78(5):1043-51 [16204623.001]
  • [Cites] Ann N Y Acad Sci. 1996 Oct 31;795:410-2 [8958969.001]
  • [Cites] CA Cancer J Clin. 2002 Mar-Apr;52(2):72-91 [11929007.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1345-50 [16762946.001]
  • [Cites] Oncologist. 2007;12 Suppl 1:22-34 [17573453.001]
  • [Cites] Transpl Immunol. 1998 Sep;6(3):193-7 [9848226.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2009 May;12(3):227-31 [19339883.001]
  • (PMID = 20359252.001).
  • [ISSN] 1179-2000
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


64. Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, Fernandes JK: Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep; 2007 Mar;9(2):152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic thyroid carcinoma: an overview.
  • Thyroid cancer is an uncommon malignancy that accounts for roughly 1% of all new cancers.
  • Although anaplastic lesions constitute fewer than 5% of thyroid cancers, they represent over half of thyroid cancer-related deaths.
  • The relative rarity of anaplastic thyroid cancer, its aggressive nature, and its rapidly fatal course have contributed to the difficulty in developing effective treatment for this disease.
  • [MeSH-major] Carcinoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 1985 Jan;60(1):51-8 [3965822.001]
  • [Cites] Mol Cancer Ther. 2005 Aug;4(8):1146-56 [16093430.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):615-29 [16172195.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1110-6 [15785737.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1848-53 [12085174.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):564-6 [1985750.001]
  • [Cites] World J Surg. 1998 Jul;22(7):725-30 [9606289.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):928-35 [15562011.001]
  • [Cites] Surg Today. 2004;34(5):394-8 [15108075.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):260-4 [11373102.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2216-24 [15956966.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1559-64 [14657716.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):1243-5 [15699543.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1330-5 [15739211.001]
  • [Cites] Thyroid. 2006 Mar;16(3):217-24 [16571083.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Mar-Apr;11(2):361-7 [2107720.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2335-42 [11413523.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] J Laryngol Otol. 2005 Aug;119(8):585-91 [16102210.001]
  • [Cites] Thyroid. 1998 Aug;8(8):715-26 [9737368.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64 [11833496.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4703-9 [15899946.001]
  • [Cites] Cancer. 2005 May 1;103(9):1785-90 [15789362.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Mar;24(1):151-4 [15943045.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):725-34 [16149875.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):464-71 [16106252.001]
  • [Cites] Histopathology. 2005 May;46(5):569-75 [15842639.001]
  • [Cites] Can J Surg. 1980 Jan;23(1):25-7 [7363154.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1137-43 [15519785.001]
  • [Cites] Cancer. 1978 Jun;41(6):2267-75 [657091.001]
  • (PMID = 17288883.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


65. Takano H, Shibamoto T, Zhang W, Kurata Y: Liver volume, as assessed by four ultrasonic crystals arranged to form a tetrahedron, decreases during anaphylactic shock in anesthetized rats. Shock; 2010 Dec;34(6):586-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The measured relative change of the tetrahedron volume (V[utc]; percentage changes of the initial volume) was closely correlated with the liver weight change (W; percentage changes of the initial liver weight): V(utc) = 0.85W - 4.11 (r² = 0.67).

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20351625.001).
  • [ISSN] 1540-0514
  • [Journal-full-title] Shock (Augusta, Ga.)
  • [ISO-abbreviation] Shock
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Aukerman DF, Aukerman MM, Browning D: Medical coverage of high school athletics in North Carolina. South Med J; 2006 Feb;99(2):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this cross-sectional study was to assess the quality and extent of medical coverage at high school athletic events in North Carolina.
  • METHODS: A questionnaire, mailed to all athletic directors at public and private North Carolina high school members of the North Carolina High School Athletic Association, was used to assess medical coverage.
  • RESULTS: Only 56% of the schools had coverage by either nationally or state certified athletic trainers.
  • Although 71% of schools had physician coverage at some athletic events, less than 10% of physician coverage included monitoring of athletic practices.
  • Only 27% of the schools surveyed felt that their existing medical coverage of athletic events could be considered adequate.
  • [MeSH-major] Athletic Injuries. Emergency Medical Services. Health Services Needs and Demand / statistics & numerical data. School Health Services / statistics & numerical data


67. Fontana GA: Downregulation of cough by exercise and voluntary hyperpnea. Lung; 2010 Jan;188 Suppl 1:S95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intensity of the urge-to-cough (UTC), a cognitive component of coughing, was also recorded throughout the trials.
  • The log-log relationship between inhaled fog concentrations and the correspondingly evoked UTC values, an index of the perceptual magnitude of the UTC sensitivity, was also calculated.
  • With exercise and VIH compared with control, mean UTC values at cough threshold were not significantly changed: control, 3.83 +/- 1.11 cm; exercise, 3.12 +/- 0.82 cm; VIH, 4.08 +/- 1.67 cm.
  • Since the slopes of the log fog concentration/log UTC value were approximately halved during exercise and VIH compared with control, the UTC sensitivity to fog was depressed (p < 0.01).


68. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M: Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res; 2007 Feb 15;13(4):1161-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
  • PURPOSE: To investigate the overall occurrence and relationship of genetic alterations in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in thyroid tumors and explore the scope of this pathway as a therapeutic target for thyroid cancer.
  • EXPERIMENTAL DESIGN: We examined collectively the major genetic alterations and their relationship in this pathway, including PIK3CA copy number gain and mutation, Ras mutation, and PTEN mutation, in a large series of primary thyroid tumors.
  • RESULTS: Occurrence of any of these genetic alterations was found in 25 of 81 (31%) benign thyroid adenoma (BTA), 47 of 86 (55%) follicular thyroid cancer (FTC), 21 of 86 (24%) papillary thyroid cancer (PTC), and 29 of 50 (58%) anaplastic thyroid cancer (ATC), with FTC and ATC most frequently harboring these genetic alterations.
  • A mutual exclusivity among these genetic alterations was seen in BTA, FTC, and PTC, suggesting an independent role of each of them through the PI3K/Akt pathway in the tumorigenesis of the differentiated thyroid tumors.
  • However, coexistence of these genetic alterations was increasingly seen with progression from differentiated tumor to undifferentiated ATC.
  • Their coexistence with BRAF mutation was also frequent in PTC and ATC.
  • CONCLUSIONS: The data provide strong genetic implication that aberrant activation of PI3K/Akt pathway plays an extensive role in thyroid tumorigenesis, particularly in FTC and ATC, and promotes progression of BTA to FTC and to ATC as the genetic alterations of this pathway accumulate.
  • Progression of PTC to ATC may be facilitated by coexistence of PI3K/Akt pathway-related genetic alterations and BRAF mutation.
  • The PI3K/Akt pathway may thus be a major therapeutic target in thyroid cancers.
  • [MeSH-major] Oncogene Protein v-akt / genetics. Phosphatidylinositol 3-Kinases / genetics. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / genetics

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317825.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R0-1 CA113507-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / Oncogene Protein v-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


69. Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts AC: Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann Pharmacother; 2007 Mar;41(3):408-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total, 416 drugs metabolized by CYP2D6 were prescribed, with 257 (62%) of these classified as an antidepressant (Anatomical and Therapeutic Chemical [ATC] category N06A) or antipsychotic (ATC N05A).

  • MedlinePlus Health Information. consumer health - Antidepressants.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341534.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Antipsychotic Agents; EC 1.14.14.1 / Cytochrome P-450 CYP2D6
  •  go-up   go-down


70. Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi AR, Tavangar SM, Malekzadeh R, Larijani B: Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer; 2006 Apr-Jun;43(2):80-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine cancer in Iran: based on cancer registry system.
  • BACKGROUND: A population-based registry of endocrine cancer cases in four Iranian provinces, was performed for the years 1996-2000.
  • MATERIALS AND METHODS: Patients in each province were grouped according to age, gender and tumor specifics (site, morphology, behavior) and the data was coded according to the international classification of diseases for oncology.
  • RESULTS: A total of 319 cases of primary endocrine cancer were found and registered, including 313 cases of thyroid carcinoma and 6 cases of adrenal cancer.
  • The thyroid carcinoma group cases consisted of papillary (82.7%), follicular (8.6%), medullary (7.0%) and anaplastic (1.6%) carcinomas.
  • The ASR for thyroid carcinoma was 1.289 (0.627 for men, 1.59 for women), with the highest incidence rate in Kerman (ASR 1.643) and the lowest incidence rate in Golestan (ASR 0.735).
  • For the 6 cases of adrenal cancer, 4 were neuroblastoma and 2 were pheochromocytoma.
  • Considering the effect of improvement in the iodine intake in previously deficient communities, which is associated with an increase in the incidence of papillary carcinoma compared to other histologic types, the frequency and distribution of histologic types of thyroid carcinoma was closer to what can be seen in iodine-rich areas.
  • [MeSH-major] Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. Registries / statistics & numerical data
  • [MeSH-minor] Adenocarcinoma, Follicular / epidemiology. Adenocarcinoma, Follicular / pathology. Adolescent. Adrenal Gland Neoplasms / epidemiology. Adrenal Gland Neoplasms / pathology. Adult. Age Distribution. Aged. Carcinoma, Medullary / epidemiology. Carcinoma, Medullary / pathology. Carcinoma, Papillary. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Iodine / metabolism. Iran / epidemiology. Male. Middle Aged. Pheochromocytoma / epidemiology. Pheochromocytoma / pathology. Retrospective Studies. Sex Distribution. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16790945.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 9679TC07X4 / Iodine
  •  go-up   go-down


71. Weidner TG, Henning JM: Importance and applicability of approved clinical instructor standards and criteria to certified athletic trainers in different clinical education settings. J Athl Train; 2005 Oct-Dec;40(4):326-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance and applicability of approved clinical instructor standards and criteria to certified athletic trainers in different clinical education settings.
  • CONTEXT: For optimal clinical education of athletic training students, Clinical Instructor Educators and program directors need to proactively select, train, and evaluate their Approved Clinical Instructors (ACIs).
  • OBJECTIVE: To assess the relative importance and applicability of ACI standards to certified athletic trainers employed in different athletic training clinical education settings.
  • CONCLUSIONS: The Weidner and Henning standards are considered to be important and applicable across a variety of athletic training clinical education settings.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16404455.001).
  • [ISSN] 1062-6050
  • [Journal-full-title] Journal of athletic training
  • [ISO-abbreviation] J Athl Train
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1323295
  •  go-up   go-down


72. Haberthür C, Guttmann J: Short-term effects of positive end-expiratory pressure on breathing pattern: an interventional study in adult intensive care patients. Crit Care; 2005 Aug;9(4):R407-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In 30 tracheally intubated, spontaneously breathing patients, we sequentially applied PEEP to the trachea at 0, 5 and 10 cmH2O, and then again at 5 cmH2O for 30 s each, using the automatic tube compensation mode.
  • Post hoc analysis revealed a similar but stronger response in patients with impaired respiratory system compliance.

  • MedlinePlus Health Information. consumer health - Critical Care.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Crit Care Med. 2000 Nov;162(5):1633-40 [11069788.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Sep;160(3):950-60 [10471624.001]
  • [Cites] J Appl Physiol (1985). 2001 Jun;90(6):2330-40 [11356800.001]
  • [Cites] Crit Care Med. 2003 Nov;31(11):2619-26 [14605533.001]
  • [Cites] Technol Health Care. 2003;11(6):413-24 [14757920.001]
  • [Cites] Br Med J. 1974 Jun 22;2(5920):656-9 [4835444.001]
  • [Cites] J Appl Physiol. 1975 May;38(5):869-74 [1126897.001]
  • [Cites] J Appl Physiol. 1975 Mar;38(3):474-80 [168175.001]
  • [Cites] J Pediatr. 1977 Jun;90(6):976-81 [323448.001]
  • [Cites] Respir Physiol. 1981 Sep;45(3):343-55 [6800008.001]
  • [Cites] Am J Physiol. 1986 May;250(5 Pt 2):R902-9 [3706575.001]
  • [Cites] Respir Physiol. 1988 Aug;73(2):145-54 [3420318.001]
  • [Cites] J Appl Physiol (1985). 1990 Mar;68(3):1092-100 [2140347.001]
  • [Cites] J Appl Physiol (1985). 1991 Aug;71(2):474-80 [1938718.001]
  • [Cites] Pediatr Pulmonol. 1991;11(4):345-9 [1758760.001]
  • [Cites] J Appl Physiol (1985). 1992 Mar;72(3):881-7 [1533214.001]
  • [Cites] J Appl Physiol (1985). 1992 Aug;73(2):479-85 [1399969.001]
  • [Cites] Anesthesiology. 1993 Sep;79(3):503-13 [8363076.001]
  • [Cites] Respir Physiol. 1993 Aug;93(2):175-87 [8210757.001]
  • [Cites] Respir Med. 1996 Sep;90(8):463-6 [8869439.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):938-44 [8887589.001]
  • [Cites] J Appl Physiol (1985). 1998 Dec;85(6):2033-9 [9843523.001]
  • [Cites] Intensive Care Med. 1999 May;25(5):514-9 [10401948.001]
  • [Cites] Respiration. 2001;68(2):140-4 [11287827.001]
  • (PMID = 16137354.001).
  • [ISSN] 1466-609X
  • [Journal-full-title] Critical care (London, England)
  • [ISO-abbreviation] Crit Care
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  • [Other-IDs] NLM/ PMC1269457
  •  go-up   go-down


73. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, Iaccarino A, Russo M, Pierantoni GM, Leone V, Sacchetti S, Troncone G, Santoro M, Fusco A: Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res; 2008 Aug 15;68(16):6770-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer.
  • Using gene expression profiling, we found that the CBX7 gene was drastically down-regulated in six thyroid carcinoma cell lines versus control cells.
  • The aims of this study were to determine whether CBX7 is related to the thyroid cancer phenotype and to try to identify new tools for the diagnosis and prognosis of thyroid cancer.
  • We thus evaluated CBX7 expression in various snap-frozen and paraffin-embedded thyroid carcinoma tissues of different degrees of malignancy by quantitative reverse transcription-PCR and immunohistochemistry, respectively.
  • Indeed, it decreased in an increasing percentage of cases going from benign adenomas to papillary (PTC), follicular, and anaplastic (ATC) thyroid carcinomas.
  • This finding coincides with results obtained in rat and mouse models of thyroid carcinogenesis.
  • CBX7 loss of heterozygosity occurred in 36.8% of PTC and in 68.7% of ATC.
  • Restoration of CBX7 expression in thyroid cancer cells reduced growth rate, with a retention in the G(1) phase of the cell cycle, suggesting that CBX7 can contribute to the proliferation of the transformed thyroid cells.
  • In conclusion, loss of CBX7 expression correlates with a highly malignant phenotype in thyroid cancer patients.
  • [MeSH-major] Adenocarcinoma, Follicular / genetics. Carcinoma / genetics. Carcinoma, Papillary / genetics. Repressor Proteins / genetics. Repressor Proteins / metabolism. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adenoviridae / genetics. Animals. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Chromosomes, Human, Pair 22 / genetics. Colony-Forming Units Assay. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Gene Expression Regulation, Neoplastic. Humans. Loss of Heterozygosity. Mice. Mice, Nude. Polycomb Repressive Complex 1. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Rats. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701502.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBX7 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


74. Zhang C, Huang Y: Complete mitochondrial genome of Oxya chinensis (Orthoptera, Acridoidea). Acta Biochim Biophys Sin (Shanghai); 2008 Jan;40(1):7-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The initiation codon of the cytochrome oxidase subunit I gene in the mitochondrial genome of O. chinensis appears to be ATC, instead of the tetranucleotides that have been reported in Locusta migratoria (L. migratoria) mitochondrial genome.
  • [MeSH-major] DNA, Mitochondrial / genetics. Genome / genetics. Mitochondria / genetics. Orthoptera / classification. Orthoptera / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180849.001).
  • [ISSN] 1745-7270
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


75. Woyach JA, Shah MH: New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer; 2009 Sep;16(3):715-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapeutic advances in the management of progressive thyroid cancer.
  • The spectrum of thyroid cancers ranges from one of the most indolent to one of the most aggressive solid tumors identified.
  • Conventional therapies for thyroid cancers are based on the histologic type of thyroid cancers such as papillary or follicular thyroid cancer (differentiated thyroid cancer (DTC)), medullary thyroid cancer (MTC), or anaplastic thyroid cancer (ATC).
  • While surgery is one of the key treatments for all such types of thyroid cancers, additional therapies vary.
  • Effective targeted therapy for DTC is a decades-old practice with systemic therapies of thyroid stimulating hormone suppression and radioactive iodine therapy.
  • However, for the iodine-refractory DTC, MTC, and ATC there is no effective systemic standard of care treatment.
  • Recent advances in understanding pathogenesis of DTC and development of molecular targeted therapy have dramatically transformed the field of clinical research in thyroid cancer.
  • Over the last five years, incredible progress has been made and phases I-III clinical trials have been conducted in various types of thyroid cancers with some remarkable results that has made an impact on lives of patients with thyroid cancer.
  • Such history-making events have boosted enthusiasm and interest among researchers, clinicians, patients, and sponsors and we anticipate ongoing efforts to develop more effective and safe therapies for thyroid cancer.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma / therapy. Thyroid Neoplasms / therapy
  • [MeSH-minor] Animals. Carcinoma, Medullary / etiology. Carcinoma, Medullary / therapy. Carcinoma, Papillary / etiology. Carcinoma, Papillary / therapy. Clinical Trials as Topic / methods. Clinical Trials as Topic / trends. Disease Progression. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Models, Biological

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19218279.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 106
  •  go-up   go-down


76. Pohjanoksa-Mäntylä MK, Antila J, Eerikäinen S, Enäkoski M, Hannuksela O, Pietilä K, Airaksinen M: Utilization of a community pharmacy-operated national drug information call center in Finland. Res Social Adm Pharm; 2008 Jun;4(2):144-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority (83%) of these calls were therapeutic or pharmaceutical inquiries, with 26% concerning costs and reimbursements, 14% interactions, 14% dosages, and 11% adverse effects.
  • Nervous system drugs (Anatomical Therapeutic Chemical [ATC] classification N), anti-infectives (J), and musculoskeletal drugs (M) accounted for 20%, 18%, and 13% of the calls, respectively.
  • Nonsteroidal anti-inflammatory drugs (NSAID) (9% of the calls), antidepressants (6%), and penicillin (5%) were the most often inquired about ATC-subgroups.
  • This may especially be the case for certain population groups, and in regard to nervous system drugs, anti-infectives and NSAID.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555967.001).
  • [ISSN] 1551-7411
  • [Journal-full-title] Research in social & administrative pharmacy : RSAP
  • [ISO-abbreviation] Res Social Adm Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Perrier E, Manen O, Cinquetti G: Essential thrombocytosis and myocardial infarction in an aircrew member: aeromedical concerns. Aviat Space Environ Med; 2006 Jan;77(1):69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of a 40-yr-old, female French military air traffic controller (ATC) admitted for an ST-elevation myocardial infarction.
  • The diagnosis of ET was then established.
  • No platelet-lowering therapy was prescribed, aspirin was continued, and this ATC was considered unfit for operational duties.
  • [MeSH-major] Military Personnel. Myocardial Infarction / etiology. Thrombocytosis / diagnosis. Work Capacity Evaluation
  • [MeSH-minor] Adult. Aerospace Medicine. Aspirin / therapeutic use. Coronary Angiography. Coronary Thrombosis / radiography. Coronary Thrombosis / therapy. Female. Humans. Platelet Aggregation Inhibitors / therapeutic use. Smoking

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422458.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


78. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R: Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest; 2009 Jul;89(7):791-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas.
  • Thyroid transcription factor-1 (TTF-1), also known as NKX2-1, is a homeodomain containing transcriptional factor identified in thyroid, lung and central nervous system.
  • In the thyroid, TTF-1 is essential for thyroid organogenesis and governs thyroid functions by regulating various thyroid-specific genes.
  • We previously demonstrated that most differentiated thyroid neoplasms, including follicular adenomas/carcinomas and papillary carcinomas, express TTF-1 at both protein and mRNA levels.
  • However, certain subtypes of thyroid cancers have shown low or negative expression of TTF-1.
  • The aim of our study was to investigate the function of epigenetic modification in dysregulation of TTF-1 in thyroid carcinoma cells.
  • We evaluated the expression of TTF-1 in primary thyroid tissues (normal thyroid, papillary carcinoma and undifferentiated carcinoma) and in thyroid carcinoma cell lines using immunohistochemistry and RT-PCR.
  • We also explored whether epigenetic modifiers, including 5-aza-deoxycytidine, could restore TTF-1 expression in thyroid carcinoma cells.
  • In our current study, immunohistochemistry and RT-PCR showed positive expression of TTF-1 in normal thyroids and papillary carcinomas.
  • Meanwhile, most of the undifferentiated carcinomas and the cell lines lost TTF-1 expression.
  • No methylation in the CpG of TTF-1 promoter was detected in normal thyroids or papillary carcinomas.
  • In contrast, DNA methylation was identified in 60% of the undifferentiated carcinomas (6/10) and 50% of the cell lines (4/8).
  • ChIP assay demonstrated that acetylation of H3-lys9 was positively correlated with TTF-1 expression in thyroid carcinoma cells.
  • Finally, DNA demethylating agents could restore TTF-1 gene expression in the thyroid carcinoma cell lines.
  • Our data suggest that epigenetics is involved with inactivation of TTF-1 in thyroid carcinomas, and provide a possible means of using TTF-1 as a target for differentiation-inducing therapy through epigenetic modification.
  • [MeSH-major] DNA Methylation. Gene Silencing. Histones / metabolism. Nuclear Proteins / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism. Transcription Factors / genetics
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Base Sequence. Carcinoma, Papillary / etiology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Cell Line, Tumor. Chromatin Immunoprecipitation. CpG Islands. DNA Primers / genetics. Epigenesis, Genetic / drug effects. Gene Expression Profiling. Humans. Hydroxamic Acids / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Thyroid Gland / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506552.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Histones; 0 / Hydroxamic Acids; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


79. Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N: Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res; 2009 Dec 1;15(23):7153-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compared the response of MM cells versus several epithelial cancer models to the proteasome inhibitor bortezomib in combination with nutlin-3.
  • Importantly, however, in breast, prostate, colon, and thyroid (papillary, follicular, anaplastic, and medullary) carcinoma cell lines, this combination triggered synergistic cytotoxicity, and increased expression of p53, p21, Hdm2, Bax, Noxa, PUMA, and cleavage of caspase-3 and poly ADP ribose polymerase.
  • CONCLUSIONS: This differential response of MM versus epithelial carcinomas to combination of nutlin-3 with bortezomib sheds new light on the role of p53 in bortezomib-induced apoptosis.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6347-55 [11086072.001]
  • [Cites] Cell Death Differ. 2010 Jan;17(1):86-92 [19543236.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):673-82 [11463391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5556-71 [12897130.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Genes Dev. 1993 Jul;7(7A):1126-32 [8319905.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1646-56 [9880544.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):439-44 [15542427.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1461-6 [15608685.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3609-17 [16081689.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1092-100 [16234364.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] Blood. 2006 Aug 1;108(3):993-1000 [16543464.001]
  • [Cites] Curr Drug Targets. 2006 Oct;7(10):1341-7 [17073596.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3177-88 [17185464.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):950-68 [17546631.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3892-901 [17679727.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • (PMID = 19934289.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA050947-17A1; United States / NCI NIH HHS / CA / R01 CA050947; United States / NCI NIH HHS / CA / R01 CA050947-17A1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Imidazoles; 0 / Piperazines; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ NIHMS145802; NLM/ PMC3672410
  •  go-up   go-down


80. Kopjar N, Zeljezić D, Kasuba V, Rozgaj R: [Antineoplastic drugs as a potential risk factor in occupational settings: mechanisms of action at the cell level, genotoxic effects, and their detection using different biomarkers]. Arh Hig Rada Toksikol; 2010 Mar;61(1):121-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Classification of antineoplastic drugs according to the IARC monographs on the evaluation of carcinogenic risks to humans is accompanied by data on their mutagenicity and the most recent updates in the Anatomical Therapeutic Chemical (ATC) Classification System.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20338875.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 212
  •  go-up   go-down


81. Lin D, Ippolito GC, Zong RT, Bryant J, Koslovsky J, Tucker P: Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer. Mol Cancer; 2007 Mar 26;6:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bright positively activates IgH transcriptional initiation by binding to ATC-rich P sites within nuclear matrix attachment regions (MARs) flanking the IgH intronic enhancer (Emu).
  • A system was established in which VH promoter-driven in vitro transcription on chromatin- reconstituted templates was responsive to Emu.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5206-11 [1922040.001]
  • [Cites] Mol Cell Biol. 1991 Oct;11(10):5197-205 [1922039.001]
  • [Cites] Science. 1993 Jul 2;261(5117):82-6 [8316859.001]
  • [Cites] Genes Dev. 1993 Oct;7(10):2016-32 [8406005.001]
  • [Cites] Science. 1994 Aug 26;265(5176):1221-5 [8066460.001]
  • [Cites] J Immunol. 1995 Nov 1;155(9):4270-7 [7594585.001]
  • [Cites] Genes Dev. 1995 Dec 15;9(24):3067-82 [8543152.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):25041-8 [8798787.001]
  • [Cites] EMBO J. 1996 Sep 16;15(18):5014-21 [8890174.001]
  • [Cites] Nature. 1997 Jan 16;385(6613):269-72 [9000077.001]
  • [Cites] Mol Cell Biol. 1997 May;17(5):2658-68 [9111336.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3527-35 [9199288.001]
  • [Cites] J Immunol. 1998 May 15;160(10):4747-54 [9590220.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3596-603 [9584200.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5121-7 [9710596.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4858-62 [9988726.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1526-31 [9990057.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15633-45 [10336460.001]
  • [Cites] Methods Enzymol. 1999;304:399-414 [10372373.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1998;63:515-24 [10384316.001]
  • [Cites] Immunity. 1999 Jul;11(1):11-20 [10435575.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3741-7 [10446990.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6632-41 [10490602.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2834-42 [15728493.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2073-84 [15743806.001]
  • [Cites] Genomics. 2005 Aug;86(2):242-51 [15922553.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14362-7 [16186486.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2187-201 [16507996.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4758-68 [16738337.001]
  • [Cites] Science. 1994 Sep 9;265(5178):1573-7 [8079170.001]
  • [Cites] Genes Dev. 1994 Oct 15;8(20):2453-65 [7958909.001]
  • [Cites] Mol Cell Biol. 1995 Jun;15(6):3217-26 [7760817.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):3003-14 [10580007.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1999;9(3-4):295-310 [10651246.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4123-33 [10921892.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(1):196-208 [11113195.001]
  • [Cites] Trends Biochem Sci. 2001 Jan;26(1):7-9 [11165500.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:99-107 [11232342.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1999;64:109-18 [11232275.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(8):2918-32 [11283269.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21325-30 [11294836.001]
  • [Cites] EMBO J. 2001 Nov 15;20(22):6394-403 [11707410.001]
  • [Cites] Nat Cell Biol. 2002 Feb;4(2):148-53 [11812999.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2477-87 [12193717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15030-5 [12415115.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11577-82 [14500909.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42106-14 [12907668.001]
  • [Cites] Mol Immunol. 2004 Jan;40(10):723-31 [14644098.001]
  • [Cites] J Biomol NMR. 2004 Apr;28(4):357-67 [14872127.001]
  • [Cites] Immunol Rev. 2004 Aug;200:182-96 [15242405.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 May;79(9):2996-3000 [6806821.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Nature. 1986 Oct 9-15;323(6088):548-51 [3093895.001]
  • [Cites] J Biol Chem. 1987 Apr 15;262(11):5394-7 [3031052.001]
  • [Cites] Mol Cell Biol. 1987 Jul;7(7):2558-67 [3039350.001]
  • [Cites] Genes Dev. 1988 Oct;2(10):1227-37 [3264542.001]
  • [Cites] Genes Dev. 1989 Aug;3(8):1255-66 [2792763.001]
  • [Cites] Mol Cell Biol. 1990 Mar;10(3):982-90 [2304473.001]
  • [Cites] Nucleic Acids Res. 1990 May 11;18(9):2643-8 [2111008.001]
  • [Cites] EMBO J. 1993 Jun;12(6):2321-7 [8508765.001]
  • (PMID = 17386101.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA110624; United States / NCI NIH HHS / CA / R01 CA031534; United States / NCI NIH HHS / CA / 1F32CA110624-01A1; United States / NCI NIH HHS / CA / CA31534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ARID3A protein, human; 0 / Chromatin; 0 / DNA-Binding Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Trans-Activators; 0 / Transcription Factors; EC 3.1.- / Deoxyribonucleases
  • [Other-IDs] NLM/ PMC1852116
  •  go-up   go-down


82. Zhu XG, Cheng SY: Modeling thyroid cancer in the mouse. Horm Metab Res; 2009 Jun;41(6):488-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling thyroid cancer in the mouse.
  • Thyroid carcinomas, the most common endocrine tumors in humans, have an increasing incidence in the U.S. and worldwide.
  • There are four major types of thyroid cancers: papillary, follicular, anaplastic, and medullary carcinomas.
  • In recent years, significant progress has been made in the identification of genetic alterations in thyroid carcinomas, particularly, papillary and medullary thyroid cancers.
  • Mouse models of thyroid cancer are valuable tools in elucidating molecular genetic changes underlying thyroid carcinogenesis and in identifying potential molecular targets for therapeutic intervention.
  • Representative mouse models of papillary, follicular, and medullary carcinomas are reviewed here with particular emphasis on those for follicular thyroid carcinomas.
  • Challenges for further development in the modeling of thyroid cancer will also be discussed.
  • [MeSH-major] Carcinoma / pathology. Disease Models, Animal. Mice. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2002 Winter;13(4):271-88 [12665646.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Dev Dyn. 2003 Jul;227(3):367-78 [12815622.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4777-80 [12941793.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6542-52 [12944480.001]
  • [Cites] Trends Endocrinol Metab. 2003 Sep;14(7):327-33 [12946875.001]
  • [Cites] Carcinogenesis. 2003 Sep;24(9):1467-79 [12869418.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5 [12970322.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5274-80 [14500358.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):58-62 [14736524.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 31;213(1):31-45 [15062572.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4430-8 [15231697.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):263-74 [15380517.001]
  • [Cites] Endocr Rev. 2004 Oct;25(5):722-46 [15466939.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Acta Biomed. 2004 Aug;75(2):114-7 [15481700.001]
  • [Cites] Adv Exp Med Biol. 1986;206:529-42 [3591538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5923-7 [3112776.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] Oncogene. 1990 Apr;5(4):565-70 [2183158.001]
  • [Cites] Mol Endocrinol. 1990 Oct;4(10):1474-9 [2283998.001]
  • [Cites] Endocrinology. 1991 Sep;129(3):1391-401 [1714832.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Nov;73(5):990-4 [1682340.001]
  • [Cites] J Clin Invest. 1991 Dec;88(6):2123-30 [1661299.001]
  • [Cites] EMBO J. 1992 Feb;11(2):537-42 [1371462.001]
  • [Cites] Development. 1991 Dec;113(4):1093-104 [1811929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6232-6 [1631115.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5523-7 [8221693.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2979-85 [8187085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10488-92 [7937980.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1146-51 [7867001.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1789-97 [7753555.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):376-85 [7795643.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):375-8 [8536638.001]
  • [Cites] Oncogene. 1995 Dec 21;11(12):2459-67 [8545102.001]
  • [Cites] Oncogene. 1996 Jan 4;12(1):111-8 [8552381.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1821-6 [8622903.001]
  • [Cites] J Clin Endocrinol Metab. 1996 May;81(5):2006-9 [8626874.001]
  • [Cites] Oncogene. 1996 Oct 3;13(7):1471-82 [8875985.001]
  • [Cites] Endocrinology. 1997 Jan;138(1):369-78 [8977426.001]
  • [Cites] Toxicol Pathol. 1997 Jan-Feb;25(1):39-48 [9061850.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):307-18 [9121114.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3330-5 [9096393.001]
  • [Cites] Horm Res. 1997;47(4-6):137-9 [9167944.001]
  • [Cites] Endocrinology. 1997 Aug;138(8):3133-40 [9231760.001]
  • [Cites] Oncogene. 1998 Jan 15;16(2):167-77 [9464534.001]
  • [Cites] Oncogene. 1998 Sep 24;17(12):1625-8 [9794240.001]
  • [Cites] Biol Cell. 1998 Sep;90(5):369-80 [9835011.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5523-8 [9850089.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] Langenbecks Arch Surg. 1999 Feb;384(1):16-23 [10367625.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3659-65 [10380889.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Apr;50(4):529-35 [10468914.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46868-75 [15331589.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):319-27 [15681856.001]
  • [Cites] J Surg Oncol. 2005 Mar 1;89(3):122-9 [15719378.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4238-45 [15899815.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):703-5 [15900034.001]
  • [Cites] J Natl Cancer Inst. 2005 May 18;97(10):724-32 [15900042.001]
  • [Cites] Am J Epidemiol. 2005 Jun 1;161(11):1056-65 [15901626.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2261-8 [15880523.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):245-62 [15947100.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Sep;161(2):104-9 [16102579.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4456-63 [16002527.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Nov;5(6):927-46 [16255634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1780-5 [16446424.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2736-47 [16314832.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5467-74 [16785999.001]
  • [Cites] J Clin Invest. 2006 Nov;116(11):2972-84 [17039256.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):936-41 [16946010.001]
  • [Cites] Endocrinology. 2007 Mar;148(3):1306-12 [17170101.001]
  • [Cites] Steroids. 2007 Feb;72(2):171-9 [17169389.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):932-9 [17127711.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(17):6116-26 [17606624.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):957-77 [18045949.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2451-8 [17660507.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 [18088233.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):823-30 [17653082.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):625-32 [18402529.001]
  • [Cites] Horm Metab Res. 2008 May;40(5):323-8 [18491251.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):363-74, viii [18502331.001]
  • [Cites] Mol Cell Biol. 2008 Jul;28(14):4598-608 [18474620.001]
  • [Cites] Endocrinology. 2008 Oct;149(10):5107-17 [18583418.001]
  • [Cites] Br J Cancer. 2008 Dec 2;99(11):1874-83 [18985036.001]
  • [Cites] Cancer Invest. 2008 Nov;26(9):948-55 [18798058.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1053-60 [12651598.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):991-7 [10566554.001]
  • [Cites] Pathol Res Pract. 2000;196(1):1-7 [10674266.001]
  • [Cites] Thyroid. 2000 Jan;10(1):19-23 [10691309.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):671-7 [10934169.001]
  • [Cites] Oncogene. 2000 Aug 10;19(34):3948-54 [10951588.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] Science. 2000 Oct 6;290(5489):138-41 [11021799.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13209-14 [11069286.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5729-35 [11126359.001]
  • [Cites] Toxicol Pathol. 2001 Jan-Feb;29(1):8-33 [11215688.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):127-32 [11265751.001]
  • [Cites] EMBO Rep. 2000 Aug;1(2):133-9 [11265752.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):157-61 [11289751.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):3-16 [12114746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15462-7 [12432093.001]
  • [Cites] Thyroid. 2002 Nov;12(11):963-9 [12490073.001]
  • (PMID = 19358084.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA BC011191-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Germany
  • [Number-of-references] 111
  • [Other-IDs] NLM/ NIHMS405500; NLM/ PMC3464089
  •  go-up   go-down


83. Sinorita H, Madiyan M, Pramono RB, Purnama LB, Ikhsan MR, Asdie AH: ACE gene insertion/deletion polymorphism among patients with type 2 diabetes, and its relationship with metabolic syndrome at Sardjito Hospital Yogyakarta, Indonesia. Acta Med Indones; 2010 Jan;42(1):12-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine the ACE genotype of the patients, a genomic DNA fragment on intron 16 of the ACE gene was amplified by polymerase chain reaction (PCR) using a forward primer 5'-CTG GAG ACC ACT CCC ATC CTT TCT-3' and reverse primer 5'-GAT GTG GCC ATC ACA RTC GTC AGA T-3'.


84. Cruciol-Souza JM, Thomson JC: Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci; 2006;9(3):427-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Potential DDI were identified using DrugReax system.
  • Patient's age and gender, number of prescribers; number of drugs and therapeutic drug classes on prescriptions were explored as associated factors to DDI.
  • The rate of potential DDI was significantly associated to in-patients' gender [woman, Odds ratio (OR)=1.23 (P=0.035)], age=55 years old [OR=1.5 (P=0.0008)], number of therapeutic drug class (ATC code, level 1)=4 [OR=5.5 (P=0.0000), cardiology patients [OR=7.87 (P=0.0000)] hospitalized at weekends [OR=1.24 (P=0.039)] and having digoxin prescribed [OR=16.79 (P=0.0000)].
  • A positive correlation was found between DDI, patient's age, number of drugs and therapeutic action ATC codes were significant, controlling for gender (Pearson's r=0.628, P=0.001).

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207423.001).
  • [ISSN] 1482-1826
  • [Journal-full-title] Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques
  • [ISO-abbreviation] J Pharm Pharm Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


85. Goldenberg D, Zagon IS, Fedok F, Crist HS, McLaughlin PJ: Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer. Thyroid; 2008 Nov;18(11):1165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer.
  • BACKGROUND: Although thyroid cancers are readily treatable with surgery and radioactive iodine, there are problems in managing recurring, as well as locally advanced, thyroid cancer.
  • In the present study we examined the presence and distribution of OGF and OGFr in nonmedullary thyroid cancer, including papillary, follicular, and anaplastic, as well as thyroid tissue from patients with nonmalignant disease.
  • METHODS: Patient samples of thyroid cancers and goiter were collected at the time of resection and processed for immunohistochemistry of OGF and OGFr, as well as pharmacological binding assays for OGFr.
  • RESULTS: Both peptide and receptor were detected in the cytoplasm and nucleus of all nonmedullary thyroid cancers, as well as in goiter.
  • Specific and saturable binding of OGFr was found in all thyroid samples.
  • CONCLUSIONS: The finding that a potent negative growth regulator and its receptor are present in nonmedullary thyroid cancers and thyroid tissues from patients with nonmalignant disease lead us to suggest that the OGF-OGFr axis serves as a regulator of cell proliferation in these tissues.
  • Moreover, modulation of this biological system may be used to treat progression of nonmedullary thyroid neoplasias.
  • [MeSH-major] Enkephalin, Methionine / metabolism. Receptors, Opioid / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Female. Humans. Immunohistochemistry. Kinetics. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19014324.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Opioid; 0 / methionine-enkephalin receptor; 58569-55-4 / Enkephalin, Methionine
  •  go-up   go-down


86. Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E: Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf); 2006 Jan;64(1):105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
  • OBJECTIVES: The genes RET and RAS, and more recently BRAF, have been shown to be frequently mutated in human papillary thyroid carcinomas (PTC).
  • The aim of this study was to genotype for these mutations a cohort of thyroid tumours collected at our institutions.
  • DESIGN AND PATIENTS: Thyroid tumours removed from 51 subjects were analysed, including 43 PTC and 8 non-PTC tumours [3 follicular adenomas (FA), 4 follicular carcinomas (FTC) and 1 anaplastic carcinoma (AC)].
  • [MeSH-major] Carcinoma, Papillary / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402937.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


87. de Oliveira Martins S, Soares MA, Foppe van Mil JW, Cabrita J: Inappropriate drug use by Portuguese elderly outpatients--effect of the Beers criteria update. Pharm World Sci; 2006 Oct;28(5):296-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drugs were distributed mainly in the following 3 ATC (Anatomical Therapeutic Chemical Classification) classes: C (cardiovascular system), N (nervous system) and A (alimentary tract).
  • According to the ATC Classification, more than one half of the cases of inappropriateness were related with long acting benzodiazepines and with ticlopidine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 2002 Jan;50(1):26-34 [12028243.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):127-34 [11998537.001]
  • [Cites] Ann Pharmacother. 2002 Mar;36(3):404-9 [11895051.001]
  • [Cites] Arch Intern Med. 1991 Sep;151(9):1825-32 [1888249.001]
  • [Cites] Pharmacotherapy. 2000 Feb;20(2):221-8 [10678301.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2716-24 [14662625.001]
  • [Cites] Age Ageing. 2000 Jan;29(1):35-9 [10690693.001]
  • [Cites] J Am Geriatr Soc. 2004 Nov;52(11):1934-9 [15507075.001]
  • [Cites] Int J Geriatr Psychiatry. 1999 Apr;14(4):280-4 [10340189.001]
  • [Cites] BMC Geriatr. 2004 Oct 15;4:9 [15488143.001]
  • [Cites] JAMA. 1998 Oct 14;280(14):1249-52 [9786375.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2004 Oct;13(10):669-82 [15386589.001]
  • [Cites] J Am Geriatr Soc. 1994 Dec;42(12):1241-7 [7983285.001]
  • [Cites] Arch Intern Med. 1997 Jul 28;157(14):1531-6 [9236554.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Dec;1(2):61-74 [15555468.001]
  • [Cites] Ann Pharmacother. 2001 Oct;35(10):1166-72 [11675839.001]
  • [Cites] J Am Geriatr Soc. 1997 Aug;45(8):945-8 [9256846.001]
  • [Cites] Arch Intern Med. 2000 Oct 9;160(18):2825-31 [11025793.001]
  • [Cites] Eur J Intern Med. 2003 Oct;14(6):372-376 [14769496.001]
  • [Cites] J Am Pharm Assoc (Wash). 2000 May-Jun;40(3):417-24 [10853543.001]
  • [Cites] Eur J Clin Pharmacol. 2004 May;60(3):217-20 [15069591.001]
  • [Cites] Ann Pharmacother. 2002 Nov;36(11):1675-81 [12398558.001]
  • [Cites] J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6):847-57 [12482007.001]
  • [Cites] CMAJ. 1997 Feb 1;156(3):385-91 [9033421.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Sep;1(1):38-43 [15555464.001]
  • [Cites] J Clin Epidemiol. 1992 Oct;45(10):1045-51 [1474400.001]
  • (PMID = 17111245.001).
  • [ISSN] 0928-1231
  • [Journal-full-title] Pharmacy world & science : PWS
  • [ISO-abbreviation] Pharm World Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Song M, Park JE, Park SG, Lee DH, Choi HK, Park BC, Ryu SE, Kim JH, Cho S: NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun; 2009 Apr 17;381(4):491-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since DUSP26 is involved in survival of anaplastic thyroid cancer (ATC) cells, NSC-87877 could be a therapeutic reagent for treating ATC.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233143.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / NSC-87877; 0 / Quinolines; EC 3.1.3.- / Mitogen-Activated Protein Kinase Phosphatases; EC 3.1.3.48 / DUSP26 protein, human; EC 3.1.3.48 / Dual-Specificity Phosphatases; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6
  •  go-up   go-down


89. Yano Y, Kamma H, Matsumoto H, Fujiwara M, Bando H, Hara H, Yashiro T, Ueno E, Ito K, Uchida K: Growth suppression of thyroid cancer cells by adenylcyclase activator. Oncol Rep; 2007 Aug;18(2):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth suppression of thyroid cancer cells by adenylcyclase activator.
  • Thyroid stimulating hormone (TSH) is known to increase intracytoplasmic cyclic adenosine monophosphate (cAMP) and to regulate the growth of normal follicular cells.
  • The aim of this study was to explore the role of the cAMP-mediated signaling pathway stimulated by TSH as a cell growth modulator in human thyroid cancer cells.
  • One papillary thyroid cancer cell line, K1 cells and two anaplastic thyroid cancer cell lines, TTA1 and TTA2 cells were treated with forskolin, which directly activates adenyl cyclase to raise the level of intracellular cAMP.
  • Forskolin suppressed thyroid cancer cell proliferations, especially in K1 cells, in a dose-dependent manner and induced growth arrest at the G0/G1 phase of the cell cycle.
  • In conclusion, we demonstrated that forskolin was involved in G1 arrest and MAPK activation in K1 thyroid cancer cells.
  • Our study suggests that the TSH signal mediated by cAMP acts as a negative regulator in thyroid cancer cells, unlike that in normal follicular cells.
  • [MeSH-minor] Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Hepatocyte Growth Factor / pharmacology. Humans. Insulin-Like Growth Factor I / pharmacology. MAP Kinase Signaling System / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation / drug effects. Receptors, Thyrotropin / genetics. Receptors, Thyrotropin / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology. Time Factors

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611668.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Thyrotropin; 1F7A44V6OU / Colforsin; 67256-21-7 / Hepatocyte Growth Factor; 67763-96-6 / Insulin-Like Growth Factor I; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 4.6.1.1 / Adenylyl Cyclases
  •  go-up   go-down


90. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, Qian X, Sebo TJ, Erickson LA, Lloyd RV: RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest; 2005 Sep;85(9):1065-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.
  • We analyzed RASSF1A and NORE1A methylation and BRAF mutation in 89 thyroid tumors, 42 non-neoplastic thyroid tissues and three thyroid tumor cell lines using polymerase chain reaction (PCR), methylation-specific PCR, Western blotting and DNA sequencing in order to study thyroid tumor pathogenesis and progression.
  • RASSF1A promoter methylation was present in all three thyroid cell lines and in 27/78 (35%) of benign and malignant thyroid tumors.
  • We also examined for the first time NORE1A promoter region methylation in thyroid cell lines and primary tumors and showed that two of three thyroid cell lines were methylated in the NORE1A promoter region, while all primary thyroid tumors analyzed (n=51) were unmethylated.
  • BRAF mutation was present in 38% of papillary thyroid carcinomas (PTC), including 20% of PTC with a follicular variant pattern and 67% of the tall cell variant of PTC.
  • These results indicate that RASSF1A epigenetic changes are an early event in thyroid tumor pathogenesis and progression and that NORE1A methylation is uncommon in primary thyroid tumors.
  • BRAF mutation occurs later in thyroid tumor progression and is restricted mainly to PTC and anaplastic thyroid carcinoma.
  • [MeSH-major] DNA Methylation. Monomeric GTP-Binding Proteins / genetics. Mutation. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15980887.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RASSF1 protein, human; 0 / RASSF5 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  •  go-up   go-down


91. Zhang P, Martin PD, Purcarea C, Vaishnav A, Brunzelle JS, Fernando R, Guy-Evans HI, Evans DR, Edwards BF: Dihydroorotase from the hyperthermophile Aquifex aeolicus is activated by stoichiometric association with aspartate transcarbamoylase and forms a one-pot reactor for pyrimidine biosynthesis. Biochemistry; 2009 Feb 03;48(4):766-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In prokaryotes, the first three enzymes in pyrimidine biosynthesis, carbamoyl phosphate synthetase (CPS), aspartate transcarbamoylase (ATC), and dihydroorotase (DHO), are commonly expressed separately and either function independently (Escherichia coli) or associate into multifunctional complexes (Aquifex aeolicus).
  • In mammals the enzymes are expressed as a single polypeptide chain (CAD) in the order CPS-DHO-ATC and associate into a hexamer.
  • This study presents the three-dimensional structure of the noncovalent hexamer of DHO and ATC from the hyperthermophile A. aeolicus at 2.3 A resolution.
  • In the crystal structure, six DHO and six ATC chains form a hollow dodecamer, in which the 12 active sites face an internal reaction chamber that is approximately 60 A in diameter and connected to the cytosol by narrow tunnels.

  • Hazardous Substances Data Bank. OROTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Genet. 2000 Jan;16(1):9-11 [10637623.001]
  • [Cites] Proteins. 1999 Dec 1;37(4):729-42 [10651286.001]
  • [Cites] Methods Enzymol. 2001;331:248-70 [11265467.001]
  • [Cites] Biochemistry. 2001 Jun 19;40(24):6989-97 [11401542.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41 [11517324.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1451-6 [11567159.001]
  • [Cites] Reproduction. 2002 Jun;123(6):757-68 [12052230.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24490-8 [11959858.001]
  • [Cites] J Synchrotron Radiat. 2003 Jan 1;10(Pt 1):23-5 [12511787.001]
  • [Cites] Proteins. 2003;53 Suppl 6:491-6 [14579338.001]
  • [Cites] Curr Opin Struct Biol. 2003 Dec;13(6):665-73 [14675543.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52924-34 [14534296.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33035-8 [15096496.001]
  • [Cites] Nature. 1968 Jun 22;218(5147):1119-21 [5656633.001]
  • [Cites] Arch Biochem Biophys. 1969 Nov;134(2):352-65 [4311178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 May;72(5):1712-6 [168571.001]
  • [Cites] J Biol Chem. 1980 Dec 10;255(23):11372-80 [6108322.001]
  • [Cites] J Biol Chem. 1980 Dec 10;255(23):11381-95 [6108323.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6802-6 [2995985.001]
  • [Cites] Methods Enzymol. 1985;113:627-35 [3937019.001]
  • [Cites] J Mol Biol. 1985 Dec 20;186(4):715-24 [3912514.001]
  • [Cites] J Biol Chem. 1986 May 5;261(13):6073-83 [2871022.001]
  • [Cites] Science. 1988 Aug 5;241(4866):669-74 [3041592.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):46-50 [2643106.001]
  • [Cites] Trends Biochem Sci. 1990 Feb;15(2):53-9 [2186515.001]
  • [Cites] Science. 1992 Mar 20;255(5051):1544-50 [1549782.001]
  • [Cites] J Biol Chem. 1995 Jun 30;270(26):15620-7 [7797560.001]
  • [Cites] J Mol Graph. 1996 Feb;14(1):33-8, 27-8 [8744570.001]
  • [Cites] J Bacteriol. 1997 Jun;179(11):3470-81 [9171389.001]
  • [Cites] Eur J Biochem. 1997 Aug 1;247(3):1063-73 [9288932.001]
  • [Cites] Comp Biochem Physiol A Physiol. 1997 Nov;118(3):463-73 [9406429.001]
  • [Cites] Protein Sci. 1998 May;7(5):1083-91 [9605313.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1998 Jul 1;54(Pt 4):547-57 [9761849.001]
  • [Cites] Adv Microb Physiol. 1998;40:281-351 [9889981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1240-5 [9990008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5388-93 [10318893.001]
  • [Cites] Science. 1999 Jul 30;285(5428):751-3 [10427000.001]
  • [Cites] Curr Microbiol. 1999 Oct;39(4):175-9 [10486051.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53136-44 [15381710.001]
  • [Cites] Biochemistry. 2004 Dec 28;43(51):16285-92 [15610022.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):523-33 [15826651.001]
  • [Cites] J Mol Biol. 2005 May 6;348(3):535-47 [15826652.001]
  • [Cites] Biochemistry. 2005 May 3;44(17):6383-91 [15850372.001]
  • [Cites] Bioinformatics. 2005 Jun 15;21(12):2832-8 [15802286.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1668-88 [16200636.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1701-18 [16211538.001]
  • [Cites] Proteins. 2005 Dec 1;61(4):704-21 [16231289.001]
  • [Cites] BMC Bioinformatics. 2006;7:316 [16792811.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):108-17 [17164533.001]
  • [Cites] Biophys J. 2007 Mar 1;92(5):1792-805 [17172310.001]
  • [Cites] Proteins. 2007 Mar 1;66(4):824-37 [17154422.001]
  • [Cites] Science. 2007 Apr 13;316(5822):254-61 [17431175.001]
  • [Cites] Curr Opin Struct Biol. 2007 Jun;17(3):370-7 [17574831.001]
  • [Cites] J Mol Biol. 2007 Sep 21;372(3):774-97 [17681537.001]
  • [Cites] Science. 2008 Jun 13;320(5882):1428-9 [18556536.001]
  • (PMID = 19128030.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 3D6N
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060371; United States / NHLBI NIH HHS / HL / R01 HL057527; United States / NHLBI NIH HHS / HL / HL47399; United States / NHLBI NIH HHS / HL / HL57527; United States / NIGMS NIH HHS / GM / R01 GM047399; United States / NCI NIH HHS / CA / CA60321; United States / NIGMS NIH HHS / GM / GM60321; United States / NIGMS NIH HHS / GM / GM47399
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Multienzyme Complexes; 0 / Pyrimidines; 155-54-4 / 4,5-dihydroorotic acid; 61H4T033E5 / Orotic Acid; EC 2.1.3.2 / Aspartate Carbamoyltransferase; EC 3.5.2.3 / Dihydroorotase
  • [Other-IDs] NLM/ NIHMS529265; NLM/ PMC3863388
  •  go-up   go-down


92. Roche B, Larroumets G, Dejax C, Kwiatkowsi F, Desbiez F, Thieblot P, Tauveron I: Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the literature. Ann Endocrinol (Paris); 2010 Feb;71(1):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the literature.
  • OBJECTIVE: The aim of this study is to retrospectively describe the epidemiological and clinical features, therapeutic modalities, prognostic factors and survival figures in a population of patients with anaplastic thyroid carcinoma (ATC) observed in Auvergne, France.
  • MATERIAL AND METHODS: The analysis was conducted based on a computer database containing a regional register recorded by health professionals treating ATC.
  • RESULTS: Of the 1500 cancers observed over 16 years, 26 were identified as ATC.
  • The male/female ratio was 1/2.7 and the average age: 72.1; 76.9% of the cases had thyroid medical history, average tumor size at diagnosis was 7.35 cm with N1 in the course of illness in 61.5% of cases, M1 in 34.6% of cases.
  • [MeSH-major] Carcinoma / therapy. Thyroid Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19959159.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


93. Roswall P, Bu S, Rubin K, Landström M, Heldin NE: 2-methoxyestradiol induces apoptosis in cultured human anaplastic thyroid carcinoma cells. Thyroid; 2006 Feb;16(2):143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-methoxyestradiol induces apoptosis in cultured human anaplastic thyroid carcinoma cells.
  • Anaplastic thyroid carcinoma (ATC) is one of the most malignant tumors in humans, and currently there is no effective treatment.
  • In the present study we investigated the effect of an endogenous estrogen metabolite, 2-methoxyestradiol (2-ME), on the growth of human ATC cells.
  • 2-ME treatment had a strong growth inhibitory effect on five human ATC cell lines (HTh7, HTh 74, HTh83, C643, and SW1736), but showed no effect on one cell line (KAT-4).
  • Taken together, our data demonstrate an antiproliferative and apoptotic effect of 2-ME on ATC cells involving activation of MAPKs.
  • [MeSH-major] Apoptosis. Carcinoma / drug therapy. Carcinoma / metabolism. Estradiol / analogs & derivatives. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Caspase 3. Caspase 8. Caspases / metabolism. Cell Line, Tumor. DNA Fragmentation. Flow Cytometry. G1 Phase. Humans. In Situ Nick-End Labeling. MAP Kinase Signaling System. Models, Statistical. Osmosis. RNA, Messenger / metabolism. Ribonucleases / metabolism. Time Factors. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16676399.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.1.- / Ribonucleases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  •  go-up   go-down


94. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA, Timiryasova T, Chen N, Shah JP, Szalay AA, Fong Y, Wong RJ: Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery; 2007 Dec;142(6):976-83; discussion 976-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus.
  • BACKGROUND: Anaplastic thyroid carcinoma (ATC) is a fatal disease resistant to all conventional treatments.
  • Infection of 6 ATC cell lines by GLV-1h68 was detected in vitro at 12, 24, and 36 hours.
  • CONCLUSION: A replication-competent vaccinia virus has significant infectious and oncolytic activity against a panel of human ATC.
  • These results encourage future in vivo and clinical studies for this novel agent to treat this fatal cancer.
  • [MeSH-major] Carcinoma / therapy. Oncolytic Virotherapy / methods. Thyroid Neoplasms / therapy. Vaccinia virus / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063085.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galactosides; 0 / Indoles; 147336-22-9 / Green Fluorescent Proteins; EC 1.13.12.- / Luciferases; EC 3.2.1.23 / beta-Galactosidase; V595OG374W / 5-bromo-4-chloro-3-indolyl beta-galactoside
  •  go-up   go-down


95. Weijers G, Starke A, Haudum A, Thijssen JM, Rehage J, De Korte CL: Interactive vs. automatic ultrasound image segmentation methods for staging hepatic lipidosis. Ultrason Imaging; 2010 Jul;32(3):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interactive vs. automatic ultrasound image segmentation methods for staging hepatic lipidosis.
  • The aim of this study was to test the hypothesis that automatic segmentation of vessels in ultrasound (US) images can produce similar or better results in grading fatty livers than interactive segmentation.
  • A study was performed in postpartum dairy cows (N=151), as an animal model of human fatty liver disease, to test this hypothesis.
  • Ultrasonic tissue characterization (UTC) parameters--Mean echo level, standard deviation (SD) of echo level, signal-to-noise ratio (SNR), residual attenuation coefficient (ResAtt) and axial and lateral speckle size--were derived using a computer-aided US (CAUS) protocol and software package.
  • Automatic-segmentation algorithms were implemented and it was investigated whether better results could be achieved than with the subjective and time-consuming interactive-segmentation procedure.
  • The automatic-segmentation algorithms were based on both fixed and adaptive thresholding techniques in combination with a 'speckle'-shaped moving-window exclusion technique.
  • This enabled us to study the effect of the applied postprocessing steps on single and multiple linear regressions ofthe various UTC parameters with TAG.
  • Improved correlations for all US parameters were found by using automatic-segmentation techniques.
  • Best speckle-size estimates and overall performance (R2 = 0.71, AUC = 0.94) were achieved by using an SNR-based adaptive automatic-segmentation method (used TAG threshold: 50 mg/g liver wet weight).
  • Automatic segmentation is thus feasible and profitable.
  • [MeSH-minor] Algorithms. Animals. Area Under Curve. Biopsy. Cattle. Disease Models, Animal. Female. Linear Models. ROC Curve. Sensitivity and Specificity. Software. Triglycerides / metabolism. Ultrasonography

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718244.001).
  • [ISSN] 0161-7346
  • [Journal-full-title] Ultrasonic imaging
  • [ISO-abbreviation] Ultrason Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Triglycerides
  •  go-up   go-down


96. Sakji S, Letord C, Pereira S, Dahamna B, Joubert M, Darmoni J: Drug information portal in Europe: information retrieval with multiple health terminologies. Stud Health Technol Inform; 2009;150:497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIP has created specific functionalities related to drug and used specific drugs terminologies and classifications: the ATC classification, the CAS numbers, the French codes CIS, and CIP, as well as trade names and the International Nonproprietary Names of the drugs.

  • MedlinePlus Health Information. consumer health - Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745361.001).
  • [ISSN] 0926-9630
  • [Journal-full-title] Studies in health technology and informatics
  • [ISO-abbreviation] Stud Health Technol Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


97. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M, Myers JN: Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther; 2005 Apr;4(4):632-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.
  • Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human malignancies with a mean survival of only 6 months.
  • The poor prognosis of patients with ATC reflects the current lack of curative therapeutic options and the need for development of novel therapeutic strategies.
  • In this study, we report the results of a preclinical study of AEE788, a dual inhibitor of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, against ATC.
  • AEE788 was able to inhibit the proliferation and induce apoptosis of ATC cell lines in vitro.
  • ATC xenografts inhibited the growth of ATC xenografts by 44% and 69%, respectively, compared with the control group.
  • The microvessel density within the ATC xenografts was decreased by >80% in the mice treated with AEE788 alone and in combination with paclitaxel compared with the control group.
  • Considering the fact that curative options seldom exist for patients with ATC, concurrent inhibition of EGFR and VEGFR tyrosine kinases seems to be a valid and promising anticancer strategy for these patients.
  • [MeSH-major] Carcinoma / drug therapy. Purines / pharmacology. Thyroid Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827337.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097007A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AEE 788; 0 / Antineoplastic Agents; 0 / Purines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


98. Ahlstrom U: Work domain analysis for air traffic controller weather displays. J Safety Res; 2005;36(2):159-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Adverse weather conditions have a major impact on National Airspace System (NAS) operations.
  • They create safety hazards for pilots, constrain the usable airspace for air traffic control (ATC), and reduce the overall capacity of the NAS.
  • A system-wide dissemination of weather information to controllers could theoretically improve safety and efficiency.
  • Furthermore, no previous research has empirically evaluated optimal presentation designs for ATC weather displays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878775.001).
  • [ISSN] 0022-4375
  • [Journal-full-title] Journal of safety research
  • [ISO-abbreviation] J Safety Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Molander L, Gerstrand M, Rudén C: WikiPharma - a freely available, easily accessible, interactive and comprehensive database for environmental effect data for pharmaceuticals. Regul Toxicol Pharmacol; 2009 Dec;55(3):367-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The database currently contains basic information, i.e. substance name, ATC code(s) and pharmaceutical group(s), for 831 APIs representing 35 different drug classes.
  • [MeSH-minor] Environmental Exposure / adverse effects. Humans. Sweden. Water Pollutants, Chemical / adverse effects

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720105.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Water Pollutants, Chemical
  •  go-up   go-down


100. Burnett S, Blakemore SJ: Functional connectivity during a social emotion task in adolescents and in adults. Eur J Neurosci; 2009 Mar;29(6):1294-301
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this fMRI study we investigated functional connectivity between components of the mentalising system during a social emotion task, using psychophysiological interaction (PPI) analysis.
  • In both adults and adolescents, an anterior rostral region of medial prefrontal cortex (arMPFC) involved in mentalising showed greater connectivity with the posterior superior temporal sulcus (pSTS) bordering on the temporo-parietal junction (TPJ) and with anterior temporal cortex (ATC) during social than during basic emotion.
  • This result provides novel evidence that components of the mentalising system interact functionally during a social emotion task.
  • The adolescent group showed stronger connectivity between arMPFC and pSTS/TPJ during social relative to basic emotion than did the adult group, suggestive of developmental changes in functional integration within the mentalising system.

  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • SciCrunch. NeuroSynth: Data: Activation Foci .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Neurosci. 1999 Oct;2(10):861-3 [10491603.001]
  • [Cites] J Comp Neurol. 1999 Aug 2;410(3):343-67 [10404405.001]
  • [Cites] Cogn Behav Neurol. 2005 Mar;18(1):68-78 [15761278.001]
  • [Cites] Neuropsychologia. 2005;43(10):1391-9 [15936784.001]
  • [Cites] Nat Rev Neurosci. 2006 Apr;7(4):268-77 [16552413.001]
  • [Cites] Neuroimage. 2006 Apr 15;30(3):1059-68 [16337813.001]
  • [Cites] Behav Brain Res. 2007 Jul 19;181(1):12-22 [17467816.001]
  • [Cites] Neuroimage. 2007 Jul 15;36(4):1065-73 [17513132.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13507-12 [17679691.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):4028-32 [18322013.001]
  • [Cites] Nat Rev Neurosci. 2008 Apr;9(4):267-77 [18354399.001]
  • [Cites] Hum Brain Mapp. 2008 Jun;29(6):696-710 [17598163.001]
  • [Cites] Neuroimage. 2008 Jul 15;41(4):1345-51 [18495496.001]
  • [Cites] J Cogn Neurosci. 2008 Dec;20(12):2125-36 [18457502.001]
  • [Cites] Nat Rev Neurosci. 2008 Dec;9(12):947-57 [19002191.001]
  • [Cites] Hum Brain Mapp. 2009 Jan;30(1):24-37 [17979124.001]
  • [Cites] Cereb Cortex. 2009 Mar;19(3):640-57 [18653667.001]
  • [Cites] Soc Cogn Affect Neurosci. 2007 Jun;2(2):130-9 [17710201.001]
  • [Cites] J Cogn Neurosci. 2009 Sep;21(9):1736-50 [18823226.001]
  • [Cites] Soc Cogn Affect Neurosci. 2006 Sep;1(2):107-21 [18985123.001]
  • [Cites] Soc Cogn Affect Neurosci. 2007 Sep;2(3):217-26 [18985143.001]
  • [Cites] Psychol Rep. 2002 Dec;91(3 Pt 1):743-57 [12530718.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2003 Mar 29;358(1431):459-73 [12689373.001]
  • [Cites] Eur J Neurosci. 2003 Jun;17(11):2475-80 [12814380.001]
  • [Cites] Neuroimage. 2003 Aug;19(4):1835-42 [12948738.001]
  • [Cites] Brain Res Cogn Brain Res. 2003 Dec;18(1):48-57 [14659496.001]
  • [Cites] Neuroreport. 2004 Feb 9;15(2):219-23 [15076740.001]
  • [Cites] Brain Res. 1979 Mar 16;163(2):195-205 [427544.001]
  • [Cites] Neurosci Lett. 1982 Dec 13;33(3):247-52 [7162689.001]
  • [Cites] Arch Gen Psychiatry. 1994 Jun;51(6):477-84 [8192550.001]
  • [Cites] Neuroreport. 1995 Sep 11;6(13):1741-6 [8541472.001]
  • [Cites] Exp Brain Res. 1997 Jul;115(3):430-44 [9262198.001]
  • [Cites] J Comp Neurol. 1997 Oct 20;387(2):167-78 [9336221.001]
  • [Cites] Neuroimage. 1997 Oct;6(3):218-29 [9344826.001]
  • [Cites] Percept Mot Skills. 2004 Oct;99(2):371-91 [15560325.001]
  • (PMID = 19302165.001).
  • [ISSN] 1460-9568
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2695858
  •  go-up   go-down






Advertisement